A Phase 2 interventional study of Amlitelimab and Placebo in Eczema and Atopic Dermatitis, sponsored by Kymab Limited. Completed at 103 sites in 12 countries. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2025-07-03.
Sponsored by Kymab Limited (part of Sanofi) · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 72 studies in Eczema with a site in Poland — 5 open to participants now, 10 under way, 4 of them phase 3. Eczema · Poland.
Among the 72 studies in Eczema with a site in Poland, this one is the 25th largest by enrollment, is one of 7 that started in 2021, is one of 24 in phase 2, and was the 37th registered.
506 studies on the registry are indexed under Eczema; 90 are open to participants now.
Browse Eczema studies →5 of the 72 studies in Eczema with a site in Poland are open now. Recruiting first, the newest first:
Apollo Therapeutics Ltd · Sites in Poland, United States, Bulgaria and 5 more countries
Ages 18–65
Pfizer · Sites in Poland, United States, China and 4 more countries
Ages 2–11
Pfizer · Sites in Poland, United States, Bulgaria and 6 more countries
Ages 18–64
Novartis Pharmaceuticals · Sites in Poland, United States, Argentina and 14 more countries
Ages 18–100
Eli Lilly and Company · Sites in Poland, United States, Argentina and 10 more countries
Ages 6 mo–18 yrs
A study can be open while its sites in Poland have not opened yet or have stopped. Only those recruiting at a site in Poland →
Of the 66 Eczema studies recruiting now, 31 (47%) set no upper age limit and 27 (41%) stop at 75 or younger; 35 take children under 18; 22 take healthy volunteers.
This study: 18 Years to 75 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
72 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 1 · Phase 2 26 · Phase 3 40
First in 2011; this study’s year is marked. 7 started in 2021.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 390 is above the median of 91 across 403 interventional studies indexed under Eczema.
Median enrollment 290 across the 72 interventional studies. Of the 60 that completed or were terminated, 45 (75%) have results posted.
This tab as a report to print or save as PDF → With an account.
69 of 72 have an industry lead sponsor. The 10 most frequent:
This study is registered under Kymab Limited, one of the names counted as Sanofi. Under that name alone:
Kymab Limited is the lead sponsor of 5 studies on the registry; none are open to participants now.
Sanofi has 1 study filed under Eczema — fewer than ten, so there is no comparison to draw.
3 of the studies in Eczema with a site in Poland that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06807268Phase 3PfizerA Study of the Medicine Called Abrocitinib in Children 6 to Less Than 12 Years of Age With Moderate-to-Severe Eczema | 2027-05-02 |
| NCT07105488Bluefin Biomedicine, Inc.A Study Evaluating BFB759 in Moderate to Severe Atopic Dermatitis | 2027-02-28 |
| NCT07599813Apollo Therapeutics LtdA Phase 2b Study of the Effects of Camoteskimab in Adults With Moderate-to-Severe Atopic Dermatitis | 2027-10-31 |
Add all 3 to your calendar (.ics) → With an account.
Among the 72 studies in Eczema with a site in Poland, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This is an interventional, randomized, parallel group, treatment, Phase IIb, double blind, 5-arm study to assess the effect of Anti-OX40L Monoclonal Antibody (KY1005) in adult participants with moderate to severe atopic dermatitis.
The estimated duration is 28 days for screening and then up to approximately day 477 (last dose no later than day 337+140 days safety follow-up) for all patients unless enrolled into the Long-Term Extension (LTE) protocol (NCT05492578) at either Day 169 depending on responder status or no later than Day 365 due to loss of clinical response.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
The above information is not intended to contain all considerations relevant to a patient's potential participation in a clinical trial.
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Able to have children. For women this usually means from the first period until menopause, unless permanently unable to through surgery; for men, unless permanently sterile. Read who the line is about — participants, women, men, or their partners.
Criteria about it usually ask for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Biopsy and archival tissue
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Immunosuppression
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Reproductive potential
Able to have children. For women this usually means from the first period until menopause, unless permanently unable to through surgery; for men, unless permanently sterile. Read who the line is about — participants, women, men, or their partners.
Criteria about it usually ask for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis C tests
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Every 4 weeks
Drug: Amlitelimab
Every 4 weeks
Drug: Amlitelimab
Every 4 weeks
Drug: Amlitelimab
Every 4 weeks
Drug: Amlitelimab
Every 4 weeks
Drug: Placebo
Pharmaceutical form: Injection solution Route of administration: Subcutaneous
Also known as: KY1005, SAR445229, A human anti-OX40 ligand monoclonal antibody
Pharmaceutical form: Injection solution Route of administration: Subcutaneous
Percentage Change in EASI (Eczema Area and Severity Index) From Baseline to Week 16 (Part 1)
Eczema Area and Severity Index-The EASI is an Investigator-assessed validated tool used to measure the extent (area) and severity of AD with scores from 0 to 72. Higher scores indicate worse condition.
Time frame: Baseline to week 16
Percentage Change in EASI (Eczema Area and Severity Index) From Baseline to Week 24 (Part 1)
Eczema Area and Severity Index-The EASI is an Investigator-assessed validated tool used to measure the extent (area) and severity of AD with scores from 0 to 72. Higher scores indicate worse condition.
Time frame: Baseline to week 24
Percentage of Participants With at Least a 75% Reduction From Baseline in EASI (EASI 75) at Week 16 and Week 24 (Part 1)
Eczema Area and Severity Index-The EASI is an Investigator-assessed validated tool used to measure the extent (area) and severity of AD with scores from 0 to 72. Higher scores indicate worse condition.
Time frame: Baseline to week 16 and week 24
Percentage of Participants With a Response of IGA (Investigator Global Assessment) 0 or 1 and a Reduction From Baseline ≥ 2 Points (Part 1)
The IGA is a five-point scale that provides a global clinical assessment of AD severity ranging from 0 to 4, where 0 indicates clear,1 is almost clear, 2 is mild, 3 is moderate, and 4 indicates severe AD.
Time frame: Baseline to week 16 and week 24
Percentage of Participants With Improvement (Reduction) of Weekly Average of Pruritus NRS (Numerical Rating Scale) ≥ 4 With a Baseline Pruritus of ≥ 4 From Baseline (Part 1)
The pruritus NRS is a simple assessment tool to report the intensity of their pruritus (itch) ranges from 0 to 10 with 0 being 'no itch' and 10 being the 'worst itch imaginable'.
Time frame: Baseline to week 16 and week 24
Percentage of Participants With Improvement (Reduction) of Weekly Average of Pruritus NRS (Numerical Rating Scale) ≥ 4 With a Baseline Pruritus of ≥ 4 From Baseline (Part 2)
The pruritus NRS is a simple assessment tool to report the intensity of their pruritus (itch) ranges from 0 to 10 with 0 being 'no itch' and 10 being the 'worst itch imaginable'.
Time frame: Baseline to weeks week 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, & 52
Absolute Change From Baseline in EASI (Eczema Area and Severity Index) (Part 1)
Eczema Area and Severity Index-The EASI is an Investigator-assessed validated tool used to measure the extent (area) and severity of AD with scores from 0 to 72. Higher scores indicate worse condition.
Time frame: Baseline to weeks 2, 4, 8, 12, 16, 20 and 24
Percentage Change From Baseline in EASI (Eczema Area and Severity Index) (Part 1)
Eczema Area and Severity Index-The EASI is an Investigator-assessed validated tool used to measure the extent (area) and severity of AD with scores from 0 to 72. Higher scores indicate worse condition.
Time frame: Baseline to weeks 2,4, 8,12,16, 20 and 24
Absolute Change From Baseline in EASI (Eczema Area and Severity Index) (Part 2)
Eczema Area and Severity Index-The EASI is an Investigator-assessed validated tool used to measure the extent (area) and severity of AD with scores from 0 to 72. Higher scores indicate worse condition.
Time frame: Baseline to weeks 24, 28, 32, 36, 40, 44, 48, & 52
Percentage Change From Baseline in EASI (Eczema Area and Severity Index) (Part 2)
Eczema Area and Severity Index-The EASI is an Investigator-assessed validated tool used to measure the extent (area) and severity of AD with scores from 0 to 72. Higher scores indicate worse condition.
Time frame: Baseline to weeks 24, 28, 32, 36, 40, 44, 48, & 52
Percentage of Participants With at Least a 50% Reduction From Baseline in EASI (EASI 50) (Part 1)
Eczema Area and Severity Index-The EASI is an Investigator-assessed validated tool used to measure the extent (area) and severity of AD with scores from 0 to 72. Higher scores indicate worse condition.
Time frame: Baseline to weeks 2, 4, 8, 12, 16, 20 and 24
Percentage of Participants With at Least a 75% Reduction From Baseline in EASI (EASI 75) (Part 1)
Eczema Area and Severity Index-The EASI is an Investigator-assessed validated tool used to measure the extent (area) and severity of AD with scores from 0 to 72. Higher scores indicate worse condition.
Time frame: Baseline at weeks 2, 4, 8, 12, 16, 20 and 24
Percentage of Participants With at Least a 90% Reduction From Baseline in EASI (EASI 90) (Part 1)
Eczema Area and Severity Index-The EASI is an Investigator-assessed validated tool used to measure the extent (area) and severity of AD with scores from 0 to 72. Higher scores indicate worse condition.
Time frame: Baseline to weeks 2, 4, 8, 12, 16, 20 and 24
Percentage of Participants With a 100% Reduction From Baseline in EASI (EASI 100) (Part 1)
Eczema Area and Severity Index-The EASI is an Investigator-assessed validated tool used to measure the extent (area) and severity of AD with scores from 0 to 72. Higher scores indicate worse condition.
Time frame: Baseline to weeks 2, 4, 8, 12, 16, 20 and 24
Change in IGA (Investigator Global Assessment) From Baseline to (Week 24) (Part 1)
The IGA is a five-point scale that provides a global clinical assessment of AD severity ranging from 0 to 4, where 0 indicates clear, 1 is almost clear, 2 is mild, 3 is moderate, and 4 indicates severe AD
Time frame: Baseline to weeks 2, 4, 8, 12, 16, 20, & 24
Change in IGA (Investigator Global Assessment) From Baseline (Part 2)
The IGA is a five-point scale that provides a global clinical assessment of AD severity ranging from 0 to 4, where 0 indicates clear, 1 is almost clear, 2 is mild, 3 is moderate, and 4 indicates severe AD
Time frame: Baseline to weeks 24, 28, 31, 36, 40, 44, 48 & 52
Percentage of Participants With a Score of IGA (Investigator Global Assessment) 0 or 1 and a Reduction From Baseline of ≥ 2 Points (Part 1)
The IGA is a five-point scale that provides a global clinical assessment of AD (Atopic Dermatitis) severity ranging from 0 to 4, where 0 indicates clear, 1 is almost clear, 2 is mild, 3 is moderate, and 4 indicates severe AD
Time frame: Baseline to weeks 2, 4, 8,12,16,20 & 24
Absolute Change in SCORAD (SCORing Atopic Dermatitis) Index From Baseline (Part 1)
SCORAD was used to assess the extent and severity of AD (Atopic Dermatitis). Extent and severity of eczema as well as subjective assessment of symptoms were assessed and scored. SCORAD total score ranges from 0 (absent disease) to 103 (severe disease)
Time frame: Baseline to weeks 4, 8, 12, 16, 20 & 24
Absolute Change in SCORAD (SCORing Atopic Dermatitis) Index From Baseline (Part 2)
SCORAD was used to assess the extent and severity of AD (Atopic Dermatitis). Extent and severity of eczema as well as subjective assessment of symptoms were assessed and scored. SCORAD total score ranges from 0 (absent disease) to 103 (severe disease)
Time frame: Baseline to week 24, 28, 32, 36, 40, 44, 48 & 52
Percentage Change in SCORAD (SCORing Atopic Dermatitis) Index From Baseline (Part 1)
SCORAD was used to assess the extent and severity of AD (Atopic Dermatitis). Extent and severity of eczema as well as subjective assessment of symptoms were assessed and scored. SCORAD total score ranges from 0 (absent disease) to 103 (severe disease)
Time frame: Baseline to weeks 4, 8, 12, 16, 20, & 24
Percentage Change in SCORAD (SCORing Atopic Dermatitis) Index From Baseline (Part 2)
SCORAD was used to assess the extent and severity of AD (Atopic Dermatitis). Extent and severity of eczema as well as subjective assessment of symptoms were assessed and scored. SCORAD total score ranges from 0 (absent disease) to 103 (severe disease)
Time frame: Baseline to weeks 24, 28, 32, 36, 40, 44, 48 & 52
Absolute Change in Affected Body Surface Area (BSA) From Baseline (Part 1)
Time frame: Baseline to weeks 2, 4, 8, 12, 16, 20, & 24
Absolute Change in Affected BSA From Baseline (Part 2)
Time frame: Baseline to weeks 24, 28, 32, 36, 40, 44, 48 & 52
Percentage Change in Affected BSA From Baseline (Part 1)
Time frame: Baseline to weeks 2, 4, 8, 12, 16, 20, & 24
Percentage Change in Affected BSA From Baseline (Part 2)
Time frame: Baseline to weeks 24, 28, 32, 36, 40, 44, 48 & 52
Absolute Change in Patient Oriented Eczema Measure (POEM) From Baseline (Part 1)
POEM is a 7-item (dryness, itching, flaking, cracking, sleep loss, bleeding, and weeping) questionnaire to assess frequency of disease symptoms with a scoring system of 0 to 28. The higher score indicating higher severity
Time frame: Baseline to weeks 4, 8, 12, 16, 20, & 24
Absolute Change in Patient Oriented Eczema Measure (POEM) From Baseline (Part 2)
POEM is a 7-item (dryness, itching, flaking, cracking, sleep loss, bleeding, and weeping) questionnaire to assess frequency of disease symptoms with a scoring system of 0 to 28. The higher score indicating higher severity
Time frame: Baseline to weeks 24, 32, 36, 40, 44, 48 & 52
Percentage Change in Patient Oriented Eczema Measure (POEM) From Baseline (Part 1)
POEM is a 7-item (dryness, itching, flaking, cracking, sleep loss, bleeding, and weeping) questionnaire to assess frequency of disease symptoms with a scoring system of 0 to 28. The higher score indicating higher severity
Time frame: Baseline to weeks 4, 8, 12, 16, 20, & 24
Percentage Change in Patient Oriented Eczema Measure (POEM) From Baseline (Part 2)
POEM is a 7-item (dryness, itching, flaking, cracking, sleep loss, bleeding, and weeping) questionnaire to assess frequency of disease symptoms with a scoring system of 0 to 28. The higher score indicating higher severity
Time frame: Baseline to weeks 24, 32, 36, 40. 44, 48, & 52
Absolute Change in Dermatology Life Quality Index (DLQI) From Baseline (Parts 1)
DLQI is a questionnaire with a score system of 0 to 30 the high score is indicative of poor QoL.
Time frame: Baseline to weeks 2, 8, 16, 20, & 24
Absolute Change in Dermatology Life Quality Index (DLQI) From Baseline (Part 2)
DLQI is a questionnaire with a score system of 0 to 30 the high score is indicative of poor QoL.
Time frame: Baseline to weeks 24, 28, 32, 36, 40, 44, 48, & 52
Percentage Change in Dermatology Life Quality Index (DLQI) From Baseline (Part 1)
DLQI is a questionnaire with a score system of 0 to 30 the high score is indicative of poor QoL.
Time frame: Baseline to weeks 2, 8, 16, 20, & 24
Percentage Change in Dermatology Life Quality Index (DLQI) From Baseline (Part 2)
DLQI is a questionnaire with a score system of 0 to 30 the high score is indicative of poor QoL.
Time frame: Baseline to weeks 24, 28, 32, 36, 40, 44, 48, & 52
Absolute Change in Atopic Dermatitis Control Tool (ADCT) From Baseline (Part 1)
ADCT is a questionnaire to assess patient-self-perceived control of their eczema with a total score from 0 to 24; higher scores indicate lower AD control
Time frame: Baseline to weeks 16, & 24
Absolute Change in Atopic Dermatitis Control Tool (ADCT) From Baseline (Part 2)
ADCT is a questionnaire to assess patient-self-perceived control of their eczema with a total score from 0 to 24; higher scores indicate lower AD control
Time frame: Baseline to weeks 24, 36 & 52
Percentage Change in Atopic Dermatitis Control Tool (ADCT) From Baseline (Part 1)
ADCT is a questionnaire to assess patient-self-perceived control of their eczema with a total score from 0 to 24; higher scores indicate lower AD control
Time frame: Baseline to weeks 16, & 24
Percentage Change in Atopic Dermatitis Control Tool (ADCT) From Baseline (Part 2)
ADCT is a questionnaire to assess patient-self-perceived control of their eczema with a total score from 0 to 24; higher scores indicate lower AD control
Time frame: Baseline to weeks 24, 36 & 52
Absolute Change in Hospital Anxiety and Depression Scale (HADS) From Baseline (Part 1)
The HADS is 14-item questionnaire with two subscales: anxiety \& depression. Each subscale (anxiety \& depression) ranges 0-21. The total HADS score ranges 0-42 with higher score indicating a poorer state.
Time frame: Baseline to weeks 8 16, 20, & 24
Absolute Change in Hospital Anxiety and Depression Scale (HADS) From Baseline (Part 2)
The HADS is 14-item questionnaire with two subscales: anxiety \& depression. Each subscale (anxiety \& depression) ranges 0-21. The total HADS score ranges 0-42 with higher score indicating a poorer state.
Time frame: Baseline to weeks 24, 28, 32, 36, 40, 44, 48 & 52
Percentage Change in Hospital Anxiety and Depression Scale (HADS) From Baseline (Part 1)
The HADS is 14-item questionnaire with two subscales: anxiety \& depression. Each subscale (anxiety \& depression) ranges 0-21. The total HADS score ranges 0-42 with higher score indicating a poorer state.
Time frame: Baseline to weeks 8, 16, 20, & 24
Percentage Change in Hospital Anxiety and Depression Scale (HADS) From Baseline (Part 2)
The HADS is 14-item questionnaire with two subscales: anxiety \& depression. Each subscale (anxiety \& depression) ranges 0-21. The total HADS score ranges 0-42 with higher score indicating a poorer state.
Time frame: Baseline to weeks 24, 28, 32, 36, 40, 44, 48 & 52
Absolute Change in Weekly Average of Pruritus Numerical Rating Scale (NRS) From Baseline (Part 1)
The pruritus NRS is a simple assessment tool to report the intensity of their pruritus (itch) ranges from 0 to 10 with 0 being 'no itch' and 10 being the 'worst itch imaginable'.
Time frame: Baseline to weeks 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, & 24
Absolute Change in Weekly Average of Pruritus Numerical Rating Scale (NRS) From Baseline (Part 2)
The pruritus NRS is a simple assessment tool to report the intensity of their pruritus (itch) ranges from 0 to 10 with 0 being 'no itch' and 10 being the 'worst itch imaginable'.
Time frame: Baseline to weeks 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, & 52
Percent Change in Weekly Average of Pruritus Numerical Rating Scale (NRS) From Baseline (Part 1)
The pruritus NRS is a simple assessment tool to report the intensity of their pruritus (itch) ranges from 0 to 10 with 0 being 'no itch' and 10 being the 'worst itch imaginable'.
Time frame: Baseline to weeks 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23 & 24
Percent Change in Weekly Average of Pruritus Numerical Rating Scale (NRS) From Baseline (Part 2)
The pruritus NRS is a simple assessment tool to report the intensity of their pruritus (itch) ranges from 0 to 10 with 0 being 'no itch' and 10 being the 'worst itch imaginable'.
Time frame: Baseline to weeks 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, & 52
Percentage of Participants With Improvement (Reduction) of Weekly Average of Pruritus NRS (Numerical Rating Scale) ≥ 3 With a Baseline Pruritus NRS ≥ 3 From Baseline (Part 1)
The pruritus NRS is a simple assessment tool to report the intensity of their pruritus (itch) ranges from 0 to 10 with 0 being 'no itch' and 10 being the 'worst itch imaginable'.
Time frame: Baseline to weeks 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, & 24
Incidence Rate of Loss of EASI 50 (Part 2)
The incidence rate of loss of EASI 50 is calculated for participants who achieved EASI 50 at re-randomization (week 24). The incidence rate is computed as the number of participants losing EASI 50 divided by total follow-up time. The follow-up time is defined as the duration from re-randomization (week 24) to either the first event date (loss of EASI 50) or censoring date for participants who had no events. The censoring date is defined as the earliest occurrence of: use of rescue medications and/or selected prohibited medications/ procedures impacting efficacy, or study discontinuation/ completion.
Time frame: Week 24 to week 52
Incidence Rate of Loss of EASI 75 (Part 2)
The incidence rate of loss of EASI 75 is calculated for participants who achieved EASI 75 at re-randomization (week 24). The incidence rate is computed as the number of participants losing EASI 75 divided by total follow-up time. The follow-up time is defined as the duration from re-randomization (week 24) to either the first event date (loss of EASI 75) or censoring date for participants who had no events. The censoring date is defined as the earliest occurrence of: use of rescue medications and/or selected prohibited medications/ procedures impacting efficacy, or study discontinuation/ completion.
Time frame: Week 24 to week 52
Incidence Rate of Loss of IGA 0/1 (Part 2)
The incidence rate of loss of IGA 0/1 is calculated for participants who achieved IGA 0/1 at re-randomization (week 24). The incidence rate is computed as the number of participants losing IGA 0/1 divided by total follow-up time. The follow-up time is defined as the duration from re-randomization (week 24) to either the first event date (loss of IGA 0/1) or censoring date for participants who had no events. The censoring date is defined as the earliest occurrence of: use of rescue medications and/or selected prohibited medications/ procedures impacting efficacy, or study discontinuation/ completion.
Time frame: Week 24 to week 68
Serum KY1005 Concentration Assessed Throughout the Study (Part 1)
Time frame: Baseline and at weeks 1, 2, 4, 8, 12, 16, 17, 20, & 24
Serum KY1005 Concentration Assessed Throughout the Study (Part 2)
Time frame: Baseline and at weeks 24, 25, 28, 32, 36, 40, 44, 48, & 52
Percentage of Participants With at Least One Treatment-emergent Adverse Event (TEAE) and Any Serious TEAE (Part 1)
Time frame: Baseline through week 24
Percentage of Participants With at Least One Treatment-emergent Adverse Event (TEAE) and Any Serious TEAE (Part 2)
Time frame: Week 24 through week 68
Percentage of Participants With Treatment-emergent ADA (Part 1)
Time frame: Baseline through week 24
Percentage of Participants With Treatment-emergent ADA (Part 2)
Time frame: Baseline through week 68
This study started in December 2021 and ended in February 2024. An individual participant was part of this study for about 1 year and 5 months. The study took place at 100 sites in 12 countries. Up to 350 participants (approximately 70 participants per treatment group) were planned to be enrolled.
| Milestone | 250 mg (500 mg LD) KY1005 (Part 1) | 250 mg (no LD) KY1005 (Part 1) | 125 mg KY1005 (Part 1) | 62.5 mg KY1005 (Part 1) | Placebo (Part 1) | 250 mg KY1005 Re-Randomized From the 250 mg (LD) Arm (Part 2) | Placebo Re-Randomized From the 250 mg (LD) Arm (Part 2) | 250 mg KY1005 Re-randomized From the 250 mg (No LD) Arm (Part 2) | Placebo Re-Randomized From the 250 mg (No LD) Arm (Part 2) | 125 mg KY1005 Re-randomized From the 125 mg Arm (Part 2) | Placebo Re-randomized From the 125 mg KY1005 Arm (Part 2) | 62.5 mg Re-Randomized From the 62.5 mg KY1005 Arm (Part 2) | Placebo Re-randomized From the 62.5 mg Arm (Part 2) | Placebo (Part 2) Continued From Part 1 Placebo |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Started | 77 | 78 | 77 | 79 | 79 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Randomized and treated | 77 | 78 | 77 | 78 | 78 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Re-randomized at week 24 | 47 | 40 | 45 | 42 | 16 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Completed | 68 | 62 | 69 | 67 | 57 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Not completed | 9 | 16 | 8 | 12 | 22 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Withdrew: Withdrawal by subject | 2 | 9 | 6 | 2 | 8 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Withdrew: Physician decision | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Withdrew: Adverse event | 3 | 5 | 1 | 6 | 4 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Withdrew: Unclassified | 1 | 1 | 0 | 0 | 4 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Withdrew: Randomized and not treated | 0 | 0 | 0 | 1 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Withdrew: Protocol violation | 2 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Withdrew: Lack of efficacy | 0 | 1 | 1 | 2 | 5 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Milestone | 250 mg (500 mg LD) KY1005 (Part 1) | 250 mg (no LD) KY1005 (Part 1) | 125 mg KY1005 (Part 1) | 62.5 mg KY1005 (Part 1) | Placebo (Part 1) | 250 mg KY1005 Re-Randomized From the 250 mg (LD) Arm (Part 2) | Placebo Re-Randomized From the 250 mg (LD) Arm (Part 2) | 250 mg KY1005 Re-randomized From the 250 mg (No LD) Arm (Part 2) | Placebo Re-Randomized From the 250 mg (No LD) Arm (Part 2) | 125 mg KY1005 Re-randomized From the 125 mg Arm (Part 2) | Placebo Re-randomized From the 125 mg KY1005 Arm (Part 2) | 62.5 mg Re-Randomized From the 62.5 mg KY1005 Arm (Part 2) | Placebo Re-randomized From the 62.5 mg Arm (Part 2) | Placebo (Part 2) Continued From Part 1 Placebo |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Started | 0 | 0 | 0 | 0 | 0 | 13 | 34 | 12 | 28 | 12 | 33 | 7 | 35 | 16 |
| Re-randomized and treated | 0 | 0 | 0 | 0 | 0 | 13 | 34 | 11 | 28 | 12 | 32 | 7 | 34 | 15 |
| Completed | 0 | 0 | 0 | 0 | 0 | 12 | 31 | 11 | 24 | 11 | 28 | 7 | 29 | 13 |
| Not completed | 0 | 0 | 0 | 0 | 0 | 1 | 3 | 1 | 4 | 1 | 5 | 0 | 6 | 3 |
| Withdrew: Withdrawal by subject | 0 | 0 | 0 | 0 | 0 | 0 | 2 | 0 | 0 | 0 | 2 | 0 | 2 | 2 |
| Withdrew: Other | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 1 | 0 | 0 | 1 | 0 |
| Withdrew: Lack of efficacy | 0 | 0 | 0 | 0 | 0 | 1 | 1 | 0 | 3 | 0 | 1 | 0 | 2 | 0 |
| Withdrew: Unclassified | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 |
| Withdrew: Re-randomized and not treated | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 1 | 0 | 1 | 1 |
Eczema Area and Severity Index-The EASI is an Investigator-assessed validated tool used to measure the extent (area) and severity of AD with scores from 0 to 72. Higher scores indicate worse condition.
| percentage of change | 250 mg (500 mg LD) KY1005 (Part 1) | 250 mg (no LD) KY1005 (Part 1) | 125 mg KY1005 (Part 1) | 62.5 mg KY1005 (Part 1) | Placebo (Part 1) |
|---|---|---|---|---|---|
| Percentage Change in EASI (Eczema Area and Severity Index) From Baseline to Week 16 (Part 1) | -61.5 ± 4.68 | -56.8 ± 4.59 | -51.6 ± 4.59 | -59.6 ± 4.53 | -29.4 ± 4.76 |
Eczema Area and Severity Index-The EASI is an Investigator-assessed validated tool used to measure the extent (area) and severity of AD with scores from 0 to 72. Higher scores indicate worse condition.
| percentage of change | 250 mg (500 mg LD) KY1005 (Part 1) | 250 mg (no LD) KY1005 (Part 1) | 125 mg KY1005 (Part 1) | 62.5 mg KY1005 (Part 1) | Placebo (Part 1) |
|---|---|---|---|---|---|
| Percentage Change in EASI (Eczema Area and Severity Index) From Baseline to Week 24 (Part 1) | -64.4 ± 5.17 | -52.2 ± 5.14 | -53.7 ± 5.08 | -54.4 ± 5.09 | -27.6 ± 5.29 |
Eczema Area and Severity Index-The EASI is an Investigator-assessed validated tool used to measure the extent (area) and severity of AD with scores from 0 to 72. Higher scores indicate worse condition.
| Percentage of participants | 250 mg (500 mg LD) KY1005 (Part 1) | 250 mg (no LD) KY1005 (Part 1) | 125 mg KY1005 (Part 1) | 62.5 mg KY1005 (Part 1) | Placebo (Part 1) |
|---|---|---|---|---|---|
| Week 16 | 40.3 | 38.5 | 42.9 | 40.5 | 11.4 |
| Week 24 | 54.5 | 38.5 | 49.4 | 40.5 | 17.7 |
The IGA is a five-point scale that provides a global clinical assessment of AD severity ranging from 0 to 4, where 0 indicates clear,1 is almost clear, 2 is mild, 3 is moderate, and 4 indicates severe AD.
| Percentage of participants | 250 mg (500 mg LD) KY1005 (Part 1) | 250 mg (no LD) KY1005 (Part 1) | 125 mg KY1005 (Part 1) | 62.5 mg KY1005 (Part 1) | Placebo (Part 1) |
|---|---|---|---|---|---|
| Week 16 | 22.1 | 14.1 | 19.5 | 25.3 | 5.1 |
| Week 24 | 45.5 | 33.3 | 40.3 | 29.1 | 11.4 |
The pruritus NRS is a simple assessment tool to report the intensity of their pruritus (itch) ranges from 0 to 10 with 0 being 'no itch' and 10 being the 'worst itch imaginable'.
| Percentage of participants | 250 mg (500 mg LD) KY1005 (Part 1) | 250 mg (no LD) KY1005 (Part 1) | 125 mg KY1005 (Part 1) | 62.5 mg KY1005 (Part 1) | Placebo (Part 1) |
|---|---|---|---|---|---|
| Week 16 | 24.7 | 19.2 | 20.8 | 22.8 | 5.1 |
| Week 24 | 31.2 | 24.4 | 28.6 | 27.8 | 7.6 |
The pruritus NRS is a simple assessment tool to report the intensity of their pruritus (itch) ranges from 0 to 10 with 0 being 'no itch' and 10 being the 'worst itch imaginable'.
| Percentage of participants | 250 mg KY1005 Re-Randomized From the LD Arm (Part 2) | Placebo Re-Randomized From the 250 mg (LD) Arm (Part 2) | 250 mg KY1005 Re-randomized From the 250 mg (No LD) Arm (Part 2) | Placebo Re-Randomized From the 250 mg (No LD) Arm (Part 2) | 125 mg KY1005 Re-randomized From the 125 mg Arm (Part 2) | Placebo Re-randomized From the 125 mg KY1005 Arm (Part 2) | 62.5 mg Re-Randomized From the 62.5 mg KY1005 Arm (Part 2) | Placebo Re-randomized From the 62.5 mg Arm (Part 2) | Placebo (Part 2) Continued From Part 1 Placebo |
|---|---|---|---|---|---|---|---|---|---|
| Week 24 | 53.8 | 41.2 | 75.0 | 35.7 | 58.3 | 45.5 | 71.4 | 45.7 | 25.0 |
| Week 25 | 53.8 | 41.2 | 66.7 | 39.3 | 66.7 | 39.4 | 57.1 | 37.1 | 31.3 |
| Week 26 | 53.8 | 38.2 | 66.7 | 32.1 | 58.3 | 33.3 | 71.4 | 42.9 | 25.0 |
| Week 27 | 61.5 | 35.3 | 58.3 | 28.6 | 58.3 | 39.4 | 71.4 | 37.1 | 25.0 |
| Week 28 | 61.5 | 35.3 | 66.7 | 35.7 | 58.3 | 42.4 | 57.1 | 37.1 | 25.0 |
| Week 29 | 69.2 | 38.2 | 50.0 | 25.0 | 58.3 | 45.5 | 57.1 | 40.0 | 25.0 |
| Week 30 | 61.5 | 44.1 | 58.3 | 25.0 | 66.7 | 36.4 | 42.9 | 42.9 | 18.8 |
| Week 31 | 61.5 | 41.2 | 58.3 | 25.0 | 66.7 | 36.4 | 42.9 | 40.0 | 18.8 |
| Week 32 | 61.5 | 47.1 | 50.0 | 25.0 | 75.0 | 42.4 | 71.4 | 40.0 | 18.8 |
| Week 33 | 61.5 | 47.1 | 58.3 | 28.6 | 58.3 | 42.4 | 71.4 | 40.0 | 18.8 |
| Week 34 | 61.5 | 41.2 | 75.0 | 21.4 | 75.0 | 30.3 | 42.9 | 37.1 | 25.0 |
| Week 35 | 61.5 | 41.2 | 66.7 | 21.4 | 66.7 | 39.4 | 71.4 | 34.3 | 25.0 |
| Week 36 | 61.5 | 38.2 | 58.3 | 21.4 | 66.7 | 42.4 | 71.4 | 40.0 | 25.0 |
| Week 37 | 53.8 | 41.2 | 50.0 | 28.6 | 66.7 | 42.4 | 71.4 | 37.1 | 18.8 |
| Week 38 | 53.8 | 35.3 | 50.0 | 25.0 | 58.3 | 42.4 | 71.4 | 31.4 | 18.8 |
| Week 39 | 53.8 | 41.2 | 50.0 | 25.0 | 58.3 | 39.4 | 71.4 | 31.4 | 25.0 |
| Week 40 | 53.8 | 38.2 | 33.3 | 25.0 | 58.3 | 36.4 | 28.6 | 31.4 | 25.0 |
| Week 41 | 61.5 | 35.3 | 41.7 | 28.6 | 66.7 | 39.4 | 57.1 | 34.3 | 31.3 |
| Week 42 | 53.8 | 38.2 | 50.0 | 28.6 | 66.7 | 36.4 | 42.9 | 31.4 | 25.0 |
| Week 43 | 53.8 | 35.3 | 50.0 | 28.6 | 58.3 | 36.4 | 42.9 | 34.3 | 31.3 |
| Week 44 | 61.5 | 38.2 | 41.7 | 21.4 | 75.0 | 39.4 | 42.9 | 37.1 | 25.0 |
| Week 45 | 61.5 | 41.2 | 41.7 | 21.4 | 75.0 | 36.4 | 42.9 | 40.0 | 31.3 |
| Week 46 | 53.8 | 44.1 | 50.0 | 28.6 | 50.0 | 27.3 | 42.9 | 37.1 | 31.3 |
| Week 47 | 46.2 | 38.2 | 33.3 | 28.6 | 58.3 | 30.3 | 42.9 | 45.7 | 25.0 |
| Week 48 | 38.5 | 35.3 | 41.7 | 28.6 | 66.7 | 27.3 | 57.1 | 37.1 | 25.0 |
| Week 49 | 38.5 | 41.2 | 50.0 | 35.7 | 66.7 | 30.3 | 57.1 | 40.0 | 25.0 |
| Week 50 | 38.5 | 35.3 | 50.0 | 32.1 | 66.7 | 24.2 | 57.1 | 37.1 | 25.0 |
| Week 51 | 30.8 | 32.4 | 41.7 | 28.6 | 58.3 | 27.3 | 42.9 | 34.3 | 25.0 |
| Week 52 | 46.2 | 29.4 | 41.7 | 25.0 | 66.7 | 27.3 | 57.1 | 40.0 | 25.0 |
Eczema Area and Severity Index-The EASI is an Investigator-assessed validated tool used to measure the extent (area) and severity of AD with scores from 0 to 72. Higher scores indicate worse condition.
| score on a scale | 250 mg (500 mg LD) KY1005 (Part 1) | 250 mg (no LD) KY1005 (Part 1) | 125 mg KY1005 (Part 1) | 62.5 mg KY1005 (Part 1) | Placebo (Part 1) |
|---|---|---|---|---|---|
| Week 2 | -8.49 ± 10.777 | -5.27 ± 8.485 | -6.17 ± 10.071 | -7.51 ± 8.836 | -3.98 ± 7.855 |
| Week 4 | -11.21 ± 10.612 | -8.38 ± 9.944 | -10.33 ± 10.861 | -10.27 ± 10.550 | -7.20 ± 8.510 |
| Week 8 | -15.67 ± 11.872 | -11.93 ± 11.018 | -13.77 ± 12.964 | -14.37 ± 10.054 | -7.64 ± 10.450 |
| Week 12 | -18.49 ± 12.411 | -13.84 ± 11.121 | -16.56 ± 14.062 | -16.46 ± 11.699 | -8.76 ± 9.608 |
| Week 16 | -19.71 ± 12.731 | -16.31 ± 12.329 | -15.70 ± 14.226 | -17.82 ± 11.730 | -7.47 ± 11.338 |
| Week 20 | -21.93 ± 14.283 | -16.46 ± 12.834 | -16.98 ± 15.321 | -16.76 ± 12.590 | -7.91 ± 11.163 |
| Week 24 | -21.92 ± 14.475 | -15.72 ± 12.977 | -16.91 ± 15.085 | -17.09 ± 13.088 | -7.52 ± 12.537 |
Eczema Area and Severity Index-The EASI is an Investigator-assessed validated tool used to measure the extent (area) and severity of AD with scores from 0 to 72. Higher scores indicate worse condition.
| Percentage of change | 250 mg (500 mg LD) KY1005 (Part 1) | 250 mg (no LD) KY1005 (Part 1) | 125 mg KY1005 (Part 1) | 62.5 mg KY1005 (Part 1) | Placebo (Part 1) |
|---|---|---|---|---|---|
| Week 2 | -27.94 ± 30.032 | -17.75 ± 38.988 | -19.09 ± 39.499 | -26.03 ± 34.462 | -15.26 ± 34.143 |
| Week 4 | -36.85 ± 28.901 | -29.13 ± 42.013 | -35.10 ± 34.457 | -35.49 ± 38.786 | -27.56 ± 31.037 |
| Week 8 | -50.25 ± 30.666 | -41.21 ± 41.129 | -45.96 ± 38.150 | -51.70 ± 31.046 | -28.70 ± 38.603 |
| Week 12 | -59.61 ± 30.717 | -50.15 ± 36.086 | -55.23 ± 40.218 | -57.36 ± 34.275 | -33.72 ± 35.358 |
| Week 16 | -62.35 ± 32.322 | -59.98 ± 37.444 | -52.50 ± 40.820 | -61.51 ± 31.663 | -28.25 ± 41.173 |
| Week 20 | -67.85 ± 33.135 | -57.80 ± 38.921 | -56.29 ± 43.103 | -57.87 ± 38.977 | -30.32 ± 40.486 |
| Week 24 | -68.01 ± 36.052 | -55.84 ± 40.299 | -56.72 ± 44.271 | -57.37 ± 40.225 | -28.55 ± 44.004 |
Eczema Area and Severity Index-The EASI is an Investigator-assessed validated tool used to measure the extent (area) and severity of AD with scores from 0 to 72. Higher scores indicate worse condition.
| Score on a scale | 250 mg KY1005 Re-Randomized From the LD Arm (Part 2) | Placebo Re-Randomized From the 250 mg (LD) Arm (Part 2) | 250 mg KY1005 Re-randomized From the 250 mg (No LD) Arm (Part 2) | Placebo Re-Randomized From the 250 mg (No LD) Arm (Part 2) | 125 mg KY1005 Re-randomized From the 125 mg Arm (Part 2) | Placebo Re-randomized From the 125 mg KY1005 Arm (Part 2) | 62.5 mg Re-Randomized From the 62.5 mg KY1005 Arm (Part 2) | Placebo Re-randomized From the 62.5 mg Arm (Part 2) | Placebo (Part 2) Continued From Part 1 Placebo |
|---|---|---|---|---|---|---|---|---|---|
| Week 24 | -29.65 ± 11.278 | -26.28 ± 13.353 | -27.60 ± 11.170 | -18.90 ± 11.932 | -27.10 ± 12.670 | -22.45 ± 14.998 | -25.47 ± 12.209 | -22.41 ± 12.841 | -21.47 ± 10.420 |
| Week 28 | -30.51 ± 12.422 | -26.34 ± 14.353 | -25.86 ± 13.128 | -17.29 ± 12.458 | -26.37 ± 13.067 | -22.87 ± 15.667 | -23.79 ± 10.424 | -21.75 ± 13.106 | -21.69 ± 11.918 |
| Week 32 | -29.08 ± 14.544 | -24.79 ± 15.775 | -22.99 ± 15.741 | -15.38 ± 12.620 | -27.36 ± 13.383 | -22.94 ± 14.915 | -24.94 ± 11.245 | -20.32 ± 14.189 | -19.60 ± 10.632 |
| Week 36 | -28.15 ± 15.138 | -22.78 ± 17.505 | -22.27 ± 16.368 | -14.57 ± 13.550 | -27.51 ± 13.550 | -22.99 ± 14.978 | -24.65 ± 10.801 | -20.09 ± 15.098 | -20.20 ± 10.436 |
| Week 40 | -28.54 ± 15.203 | -22.30 ± 17.908 | -22.56 ± 14.949 | -14.81 ± 13.178 | -27.96 ± 14.444 | -20.45 ± 16.659 | -25.51 ± 11.796 | -20.80 ± 14.601 | -20.05 ± 10.596 |
| Week 44 | -28.43 ± 15.061 | -22.23 ± 17.487 | -23.07 ± 15.679 | -14.49 ± 12.877 | -27.49 ± 14.324 | -19.76 ± 16.561 | -22.34 ± 11.070 | -20.70 ± 14.343 | -20.43 ± 11.007 |
| Week 48 | -22.15 ± 14.876 | -21.82 ± 17.764 | -22.24 ± 16.312 | -13.95 ± 13.596 | -27.72 ± 14.882 | -18.34 ± 16.959 | -23.88 ± 12.517 | -19.74 ± 15.277 | -19.99 ± 11.292 |
| Week 52 | -22.03 ± 14.889 | -19.59 ± 15.321 | -22.68 ± 15.418 | -13.89 ± 13.427 | -28.08 ± 16.097 | -17.30 ± 16.752 | -23.26 ± 11.789 | -20.81 ± 14.813 | -20.30 ± 11.526 |
Eczema Area and Severity Index-The EASI is an Investigator-assessed validated tool used to measure the extent (area) and severity of AD with scores from 0 to 72. Higher scores indicate worse condition.
| Percentage of change | 250 mg KY1005 Re-Randomized From the LD Arm (Part 2) | Placebo Re-Randomized From the 250 mg (LD) Arm (Part 2) | 250 mg KY1005 Re-randomized From the 250 mg (No LD) Arm (Part 2) | Placebo Re-Randomized From the 250 mg (No LD) Arm (Part 2) | 125 mg KY1005 Re-randomized From the 125 mg Arm (Part 2) | Placebo Re-randomized From the 125 mg KY1005 Arm (Part 2) | 62.5 mg Re-Randomized From the 62.5 mg KY1005 Arm (Part 2) | Placebo Re-randomized From the 62.5 mg Arm (Part 2) | Placebo (Part 2) Continued From Part 1 Placebo |
|---|---|---|---|---|---|---|---|---|---|
| Week 24 | -91.71 ± 8.539 | -81.85 ± 31.624 | -84.20 ± 16.741 | -72.72 ± 41.299 | -90.91 ± 10.585 | -74.56 ± 39.811 | -85.81 ± 10.212 | -76.74 ± 30.922 | -78.51 ± 28.977 |
| Week 28 | -93.56 ± 8.382 | -81.47 ± 32.251 | -79.34 ± 28.091 | -66.53 ± 43.437 | -87.78 ± 13.648 | -74.18 ± 42.104 | -89.88 ± 6.304 | -74.54 ± 31.665 | -76.87 ± 31.377 |
| Week 32 | -86.08 ± 24.896 | -76.51 ± 38.401 | -69.06 ± 38.468 | -58.78 ± 44.767 | -91.07 ± 13.744 | -75.64 ± 41.038 | -93.76 ± 4.960 | -68.09 ± 34.850 | -71.98 ± 33.063 |
| Week 36 | -86.56 ± 28.656 | -69.33 ± 43.838 | -66.64 ± 39.631 | -56.24 ± 46.469 | -91.22 ± 13.203 | -75.77 ± 40.984 | -93.09 ± 6.000 | -67.27 ± 40.162 | -74.93 ± 32.664 |
| Week 40 | -84.74 ± 28.948 | -65.65 ± 44.932 | -68.31 ± 38.024 | -57.39 ± 47.379 | -90.68 ± 13.737 | -64.68 ± 64.041 | -95.55 ± 5.011 | -70.11 ± 37.802 | -74.05 ± 32.343 |
| Week 44 | -84.46 ± 28.757 | -66.73 ± 44.328 | -69.41 ± 38.731 | -56.30 ± 46.700 | -90.18 ± 12.912 | -62.46 ± 63.983 | -83.57 ± 21.909 | -69.98 ± 37.145 | -72.99 ± 33.353 |
| Week 48 | -71.66 ± 40.416 | -65.18 ± 44.327 | -66.61 ± 39.645 | -53.59 ± 48.780 | -90.26 ± 12.961 | -57.47 ± 65.142 | -88.02 ± 22.234 | -66.63 ± 40.889 | -70.92 ± 33.888 |
| Week 52 | -71.22 ± 40.152 | -61.78 ± 44.406 | -68.09 ± 37.719 | -53.58 ± 48.725 | -89.09 ± 15.625 | -54.42 ± 65.177 | -86.51 ± 22.331 | -69.76 ± 38.241 | -72.04 ± 34.827 |
Eczema Area and Severity Index-The EASI is an Investigator-assessed validated tool used to measure the extent (area) and severity of AD with scores from 0 to 72. Higher scores indicate worse condition.
| Percentage of participants | 250 mg (500 mg LD) KY1005 (Part 1) | 250 mg (no LD) KY1005 (Part 1) | 125 mg KY1005 (Part 1) | 62.5 mg KY1005 (Part 1) | Placebo (Part 1) |
|---|---|---|---|---|---|
| Week 2 | 19.5 | 15.4 | 16.9 | 22.8 | 13.9 |
| Week 4 | 29.9 | 21.8 | 39.0 | 39.2 | 24.1 |
| Week 8 | 45.5 | 38.5 | 53.2 | 54.4 | 27.8 |
| Week 12 | 62.3 | 44.9 | 61.0 | 62.0 | 26.6 |
| Week 16 | 63.6 | 52.6 | 57.1 | 65.8 | 27.8 |
| Week 20 | 63.6 | 51.3 | 58.4 | 58.2 | 25.3 |
| Week 24 | 66.2 | 43.6 | 55.8 | 53.2 | 24.1 |
Eczema Area and Severity Index-The EASI is an Investigator-assessed validated tool used to measure the extent (area) and severity of AD with scores from 0 to 72. Higher scores indicate worse condition.
| Percentage of participants | 250 mg (500 mg LD) KY1005 (Part 1) | 250 mg (no LD) KY1005 (Part 1) | 125 mg KY1005 (Part 1) | 62.5 mg KY1005 (Part 1) | Placebo (Part 1) |
|---|---|---|---|---|---|
| Week 2 | 9.1 | 2.6 | 2.6 | 2.5 | 5.1 |
| Week 4 | 9.1 | 9.0 | 11.7 | 11.4 | 6.3 |
| Week 8 | 23.4 | 16.7 | 27.3 | 25.3 | 8.9 |
| Week 12 | 33.8 | 25.6 | 44.2 | 43.0 | 11.4 |
| Week 16 | 40.3 | 38.5 | 42.9 | 40.5 | 11.4 |
| Week 20 | 49.4 | 42.3 | 48.1 | 40.5 | 13.9 |
| Week 24 | 54.5 | 38.5 | 49.4 | 40.5 | 17.7 |
Eczema Area and Severity Index-The EASI is an Investigator-assessed validated tool used to measure the extent (area) and severity of AD with scores from 0 to 72. Higher scores indicate worse condition.
| Percentage of participants | 250 mg (500 mg LD) KY1005 (Part 1) | 250 mg (no LD) KY1005 (Part 1) | 125 mg KY1005 (Part 1) | 62.5 mg KY1005 (Part 1) | Placebo (Part 1) |
|---|---|---|---|---|---|
| Week 2 | 2.6 | 1.3 | 0 | 1.3 | 0 |
| Week 4 | 6.5 | 1.3 | 1.3 | 2.5 | 0 |
| Week 8 | 7.8 | 7.7 | 9.1 | 8.9 | 1.3 |
| Week 12 | 10.4 | 9.0 | 14.3 | 12.7 | 5.1 |
| Week 16 | 15.6 | 14.1 | 16.9 | 19.0 | 3.8 |
| Week 20 | 27.3 | 23.1 | 24.7 | 19.0 | 7.6 |
| Week 24 | 37.7 | 26.9 | 32.5 | 24.1 | 11.4 |
Eczema Area and Severity Index-The EASI is an Investigator-assessed validated tool used to measure the extent (area) and severity of AD with scores from 0 to 72. Higher scores indicate worse condition.
| Percentage of participants | 250 mg (500 mg LD) KY1005 (Part 1) | 250 mg (no LD) KY1005 (Part 1) | 125 mg KY1005 (Part 1) | 62.5 mg KY1005 (Part 1) | Placebo (Part 1) |
|---|---|---|---|---|---|
| Week 2 | 0 | 1.3 | 0 | 0 | 0 |
| Week 4 | 2.6 | 0 | 0 | 0 | 0 |
| Week 8 | 2.6 | 5.1 | 1.3 | 0 | 0 |
| Week 12 | 3.9 | 2.6 | 2.6 | 2.5 | 0 |
| Week 16 | 3.9 | 1.3 | 2.6 | 1.3 | 1.3 |
| Week 20 | 6.5 | 6.4 | 3.9 | 2.5 | 1.3 |
| Week 24 | 7.8 | 6.4 | 9.1 | 1.3 | 3.8 |
The IGA is a five-point scale that provides a global clinical assessment of AD severity ranging from 0 to 4, where 0 indicates clear, 1 is almost clear, 2 is mild, 3 is moderate, and 4 indicates severe AD
| Score on a scale | 250 mg (500 mg LD) KY1005 (Part 1) | 250 mg (no LD) KY1005 (Part 1) | 125 mg KY1005 (Part 1) | 62.5 mg KY1005 (Part 1) | Placebo (Part 1) |
|---|---|---|---|---|---|
| Week 2 | -0.33 ± 0.625 | -0.21 ± 0.408 | -0.29 ± 0.540 | -0.23 ± 0.481 | -0.18 ± 0.503 |
| Week 4 | -0.57 ± 0.869 | -0.38 ± 0.590 | -0.45 ± 0.620 | -0.51 ± 0.661 | -0.31 ± 0.592 |
| Week 8 | -0.79 ± 0.976 | -0.74 ± 0.829 | -0.80 ± 0.900 | -0.76 ± 0.709 | -0.32 ± 0.728 |
| Week 12 | -1.10 ± 1.024 | -0.87 ± 0.867 | -1.04 ± 1.013 | -1.00 ± 0.973 | -0.36 ± 0.660 |
| Week 16 | -1.23 ± 0.981 | -0.99 ± 0.899 | -0.96 ± 1.033 | -1.09 ± 0.969 | -0.43 ± 0.757 |
| Week 20 | -1.43 ± 1.118 | -1.17 ± 1.137 | -1.11 ± 1.120 | -1.10 ± 0.981 | -0.45 ± 0.822 |
| Week 24 | -1.48 ± 1.205 | -1.16 ± 1.241 | -1.32 ± 1.265 | -1.16 ± 1.030 | -0.49 ± 0.959 |
The IGA is a five-point scale that provides a global clinical assessment of AD severity ranging from 0 to 4, where 0 indicates clear, 1 is almost clear, 2 is mild, 3 is moderate, and 4 indicates severe AD
| Score on a scale | 250 mg KY1005 Re-randomized From the 250mg (LD) Arm (Part 2) | Placebo Re-randomized From the 250mg (LD) Arm (Part 2) | 250 mg KY1005 Re-randomized From the 250mg (No LD) Arm (Part 2) | Placebo Re-randomized From the 250mg (No LD) Arm (Part 2) | 125 mg KY1005 Re-randomized From the 125 mg Arm (Part 2) | Placebo Re-randomized From the 125 mg Arm (Part 2) | 62.5 mg KY1005 Re-randomized From the 62.5 mg Arm (Part 2) | Placebo Re-randomized From the 62.5 mg Arm (Part 2) | Placebo (Part 2) Continued From Part 1 Placebo |
|---|---|---|---|---|---|---|---|---|---|
| Week 24 | -2.31 ± 0.855 | -1.91 ± 1.026 | -2.00 ± 0.953 | -1.82 ± 1.156 | -2.42 ± 0.793 | -1.82 ± 1.131 | -2.00 ± 1.000 | -1.73 ± 0.911 | -1.63 ± 1.204 |
| Week 28 | -2.46 ± 0.967 | -2.00 ± 1.155 | -2.17 ± 1.193 | -1.46 ± 1.138 | -2.25 ± 0.965 | -1.74 ± 1.064 | -1.71 ± 0.951 | -1.47 ± 0.961 | -1.71 ± 1.383 |
| Week 32 | -2.00 ± 1.000 | -1.82 ± 1.314 | -1.73 ± 1.348 | -1.32 ± 1.188 | -2.33 ± 0.985 | -1.75 ± 1.078 | -1.71 ± 0.951 | -1.41 ± 1.160 | -1.67 ± 1.234 |
| Week 36 | -2.08 ± 1.188 | -1.70 ± 1.380 | -1.40 ± 1.174 | -1.29 ± 1.182 | -2.17 ± 1.115 | -1.81 ± 1.230 | -2.00 ± 1.000 | -1.53 ± 1.344 | -1.67 ± 1.234 |
| Week 40 | -2.08 ± 1.115 | -1.71 ± 1.395 | -1.64 ± 1.286 | -1.29 ± 1.301 | -2.36 ± 1.120 | -1.75 ± 1.164 | -1.86 ± 1.215 | -1.58 ± 1.311 | -1.53 ± 1.302 |
| Week 44 | -2.00 ± 1.155 | -1.69 ± 1.447 | -1.73 ± 1.348 | -1.32 ± 1.335 | -2.08 ± 1.084 | -1.63 ± 1.070 | -1.71 ± 1.113 | -1.58 ± 1.259 | -1.64 ± 1.393 |
| Week 48 | -1.69 ± 1.182 | -1.69 ± 1.469 | -1.60 ± 1.350 | -1.36 ± 1.367 | -2.08 ± 1.240 | -1.50 ± 1.137 | -2.00 ± 1.414 | -1.63 ± 1.351 | -1.71 ± 1.590 |
| Week 52 | -1.77 ± 1.301 | -1.55 ± 1.434 | -1.64 ± 1.286 | -1.36 ± 1.420 | -2.18 ± 1.401 | -1.48 ± 1.214 | -2.00 ± 1.155 | -1.65 ± 1.305 | -1.79 ± 1.672 |
The IGA is a five-point scale that provides a global clinical assessment of AD (Atopic Dermatitis) severity ranging from 0 to 4, where 0 indicates clear, 1 is almost clear, 2 is mild, 3 is moderate, and 4 indicates severe AD
| Percentage of participants | 250 mg (500 mg LD) KY1005 (Part 1) | 250 mg (no LD) KY1005 (Part 1) | 125 mg KY1005 (Part 1) | 62.5 mg KY1005 (Part 1) | Placebo (Part 1) |
|---|---|---|---|---|---|
| Week 2 | 1.3 | 0 | 0 | 0 | 1.3 |
| Week 4 | 5.2 | 1.3 | 1.3 | 2.5 | 2.5 |
| Week 8 | 9.1 | 9.0 | 13.0 | 5.1 | 5.1 |
| Week 12 | 16.9 | 12.8 | 19.5 | 19.0 | 3.8 |
| Week 16 | 22.1 | 14.1 | 19.5 | 25.3 | 5.1 |
| Week 20 | 33.8 | 25.6 | 27.3 | 21.5 | 8.9 |
| Week 24 | 45.5 | 33.3 | 40.3 | 29.1 | 11.4 |
SCORAD was used to assess the extent and severity of AD (Atopic Dermatitis). Extent and severity of eczema as well as subjective assessment of symptoms were assessed and scored. SCORAD total score ranges from 0 (absent disease) to 103 (severe disease)
| Score on a scale | 250 mg (500 mg LD) KY1005 (Part 1) | 250 mg (no LD) KY1005 (Part 1) | 125 mg KY1005 (Part 1) | 62.5 mg KY1005 (Part 1) | Placebo (Part 1) |
|---|---|---|---|---|---|
| Week 4 | -15.30 ± 16.517 | -12.27 ± 13.455 | -15.89 ± 14.865 | -14.43 ± 13.691 | -11.13 ± 14.243 |
| Week 8 | -22.39 ± 19.368 | -19.61 ± 17.527 | -21.49 ± 19.200 | -21.42 ± 16.956 | -12.50 ± 16.584 |
| Week 12 | -27.80 ± 19.621 | -22.31 ± 17.936 | -27.72 ± 20.084 | -26.45 ± 19.649 | -13.97 ± 16.898 |
| Week 16 | -30.12 ± 20.086 | -25.07 ± 20.233 | -26.28 ± 21.258 | -28.15 ± 19.831 | -13.85 ± 18.123 |
| Week 20 | -34.89 ± 22.369 | -28.04 ± 22.472 | -29.80 ± 23.594 | -26.71 ± 21.056 | -13.91 ± 19.325 |
| Week 24 | -36.19 ± 24.605 | -27.28 ± 22.937 | -29.96 ± 25.735 | -28.48 ± 21.793 | -15.08 ± 22.739 |
SCORAD was used to assess the extent and severity of AD (Atopic Dermatitis). Extent and severity of eczema as well as subjective assessment of symptoms were assessed and scored. SCORAD total score ranges from 0 (absent disease) to 103 (severe disease)
| Score on a scale | 250 mg KY1005 Re-randomized From the 250mg (LD) Arm (Part 2) | Placebo Re-randomized From the 250mg (LD) Arm (Part 2) | 250 mg KY1005 Re-randomized From the 250mg (No LD) Arm (Part 2) | Placebo Re-randomized From the 250mg (No LD) Arm (Part 2) | 125 mg KY1005 Re-randomized From the 125 mg Arm (Part 2) | Placebo Re-randomized From the 125mg Arm (Part 2) | 62.5 mg KY1005 Re-randomized From the 62.5 mg Arm (Part 2) | Placebo Re-randomized From the 62.5 mg Arm (Part 2) | Placebo (Part 2) Continued From Part 1 Placebo |
|---|---|---|---|---|---|---|---|---|---|
| Week 24 | -52.22 ± 14.314 | -44.25 ± 21.373 | -42.44 ± 21.879 | -36.77 ± 21.919 | -49.87 ± 13.012 | -41.65 ± 24.173 | -45.20 ± 18.017 | -38.45 ± 22.077 | -40.54 ± 23.584 |
| Week 28 | -54.19 ± 18.525 | -44.30 ± 23.737 | -43.38 ± 24.261 | -33.40 ± 23.845 | -47.15 ± 16.401 | -43.95 ± 24.475 | -41.17 ± 19.190 | -37.46 ± 23.843 | -42.98 ± 24.770 |
| Week 32 | -51.19 ± 23.086 | -41.55 ± 25.962 | -37.58 ± 27.000 | -28.31 ± 23.318 | -50.76 ± 16.285 | -44.04 ± 22.541 | -40.76 ± 17.685 | -36.72 ± 25.421 | -37.81 ± 25.964 |
| Week 36 | -49.68 ± 25.709 | -38.72 ± 27.164 | -33.91 ± 26.686 | -27.91 ± 24.154 | -52.12 ± 19.167 | -45.28 ± 23.438 | -40.09 ± 16.767 | -37.15 ± 27.483 | -39.35 ± 25.340 |
| Week 40 | -49.88 ± 26.342 | -38.96 ± 29.090 | -36.05 ± 27.550 | -30.05 ± 26.602 | -52.42 ± 19.560 | -42.93 ± 24.694 | -45.31 ± 22.710 | -37.75 ± 27.127 | -36.74 ± 25.865 |
| Week 44 | -47.38 ± 26.194 | -38.61 ± 28.602 | -37.95 ± 28.362 | -29.98 ± 26.387 | -51.14 ± 20.299 | -40.96 ± 24.470 | -36.39 ± 21.651 | -36.83 ± 27.061 | -37.47 ± 27.887 |
| Week 48 | -39.75 ± 25.447 | -38.18 ± 29.948 | -35.13 ± 27.409 | -29.71 ± 28.021 | -52.40 ± 22.250 | -38.38 ± 24.940 | -43.80 ± 27.380 | -37.64 ± 28.543 | -38.10 ± 28.181 |
| Week 52 | -40.26 ± 26.751 | -34.69 ± 28.925 | -35.04 ± 27.120 | -29.26 ± 27.488 | -50.26 ± 26.772 | -37.07 ± 25.763 | -42.26 ± 25.861 | -38.41 ± 26.915 | -39.94 ± 29.182 |
SCORAD was used to assess the extent and severity of AD (Atopic Dermatitis). Extent and severity of eczema as well as subjective assessment of symptoms were assessed and scored. SCORAD total score ranges from 0 (absent disease) to 103 (severe disease)
| Percentage of change | 250 mg (500 mg LD) KY1005 (Part 1) | 250 mg (no LD) KY1005 (Part 1) | 125 mg KY1005 (Part 1) | 62.5 mg KY1005 (Part 1) | Placebo (Part 1) |
|---|---|---|---|---|---|
| Week 4 | -22.02 ± 22.050 | -18.52 ± 20.315 | -22.76 ± 20.903 | -21.42 ± 21.101 | -16.67 ± 21.045 |
| Week 8 | -31.84 ± 24.549 | -30.00 ± 28.050 | -30.47 ± 26.260 | -32.07 ± 23.600 | -18.27 ± 23.875 |
| Week 12 | -40.32 ± 25.145 | -33.64 ± 26.502 | -39.38 ± 27.228 | -39.22 ± 26.807 | -20.70 ± 24.587 |
| Week 16 | -43.25 ± 26.555 | -37.18 ± 28.395 | -37.33 ± 29.071 | -41.44 ± 26.134 | -20.87 ± 26.791 |
| Week 20 | -49.92 ± 28.279 | -42.07 ± 32.179 | -42.30 ± 32.422 | -39.05 ± 28.347 | -20.88 ± 28.527 |
| Week 24 | -57.87 ± 32.609 | -41.04 ± 34.212 | -42.58 ± 35.812 | -41.49 ± 29.263 | -22.21 ± 33.233 |
SCORAD was used to assess the extent and severity of AD (Atopic Dermatitis). Extent and severity of eczema as well as subjective assessment of symptoms were assessed and scored. SCORAD total score ranges from 0 (absent disease) to 103 (severe disease)
| Percentage of change | 250 mg KY1005 Re-randomized From the 250mg (LD) Arm (Part 2) | Placebo Re-randomized From the 250mg (LD) Arm (Part 2) | 250 mg KY1005 Re-randomized From the 250mg (No LD) Arm (Part 2) | Placebo Re-randomized From the 250mg (No LD) Arm (Part 2) | 125 mg KY1005 Re-randomized From the 125 mg Arm (Part 2) | Placebo Re-randomized From the 125mg Arm (Part 2) | 62.5 mg KY1005 Re-randomized From the 62.5 mg Arm (Part 2) | Placebo Re-randomized From the 62.5 mg Arm (Part 2) | Placebo (Part 2) Continued From Part 1 Placebo |
|---|---|---|---|---|---|---|---|---|---|
| Week 24 | -76.47 ± 11.581 | -63.86 ± 27.005 | -60.09 ± 26.373 | -57.73 ± 34.302 | -72.55 ± 15.422 | -58.96 ± 31.260 | -66.12 ± 19.532 | -55.75 ± 26.945 | -60.13 ± 33.848 |
| Week 28 | -78.39 ± 16.236 | -63.35 ± 28.625 | -62.58 ± 32.229 | -52.12 ± 35.950 | -68.39 ± 21.143 | -61.69 ± 32.214 | -64.22 ± 18.649 | -53.98 ± 29.707 | -62.81 ± 36.300 |
| Week 32 | -72.44 ± 25.786 | -59.37 ± 33.889 | -53.42 ± 34.955 | -44.49 ± 35.890 | -74.03 ± 21.589 | -62.38 ± 31.104 | -64.07 ± 16.853 | -52.47 ± 31.788 | -56.11 ± 38.003 |
| Week 36 | -71.50 ± 31.364 | -55.13 ± 35.598 | -49.88 ± 36.111 | -43.78 ± 36.278 | -75.08 ± 21.563 | -63.79 ± 31.710 | -64.24 ± 20.730 | -53.95 ± 35.053 | -58.72 ± 36.827 |
| Week 40 | -71.43 ± 31.643 | -54.79 ± 38.533 | -51.85 ± 37.053 | -46.81 ± 39.055 | -74.34 ± 22.474 | -61.12 ± 34.217 | -70.27 ± 22.037 | -54.56 ± 34.785 | -54.24 ± 36.614 |
| Week 44 | -67.26 ± 31.749 | -54.96 ± 38.272 | -54.10 ± 37.251 | -46.95 ± 39.736 | -73.34 ± 22.409 | -57.94 ± 33.953 | -58.19 ± 33.365 | -52.89 ± 34.032 | -55.26 ± 39.204 |
| Week 48 | -59.99 ± 35.979 | -53.71 ± 39.548 | -51.66 ± 37.347 | -45.48 ± 41.426 | -74.37 ± 23.066 | -54.55 ± 34.719 | -67.92 ± 35.766 | -54.29 ± 35.851 | -56.30 ± 39.696 |
| Week 52 | -60.41 ± 36.686 | -49.90 ± 40.104 | -49.68 ± 35.129 | -44.93 ± 40.527 | -69.62 ± 29.104 | -52.47 ± 35.396 | -65.97 ± 34.709 | -56.19 ± 34.460 | -58.86 ± 40.701 |
| Percentage of body surface area | 250 mg (500 mg LD) KY1005 (Part 1) | 250 mg (no LD) KY1005 (Part 1) | 125 mg KY1005 (Part 1) | 62.5 mg KY1005 (Part 1) | Placebo (Part 1) |
|---|---|---|---|---|---|
| Week 2 | -4.50 ± 10.610 | -5.61 ± 10.165 | -9.08 ± 15.999 | -7.41 ± 12.588 | -4.84 ± 9.113 |
| Week 4 | -12.83 ± 15.922 | -10.16 ± 12.917 | -13.34 ± 17.347 | -12.51 ± 16.318 | -9.67 ± 16.941 |
| Week 8 | -19.37 ± 18.857 | -15.77 ± 17.004 | -17.55 ± 21.064 | -19.11 ± 18.253 | -10.00 ± 17.375 |
| Week 12 | -24.13 ± 18.097 | -19.54 ± 19.578 | -21.94 ± 22.715 | -24.14 ± 19.903 | -11.46 ± 17.035 |
| Week 16 | -26.91 ± 20.286 | -22.71 ± 21.966 | -21.74 ± 24.799 | -26.04 ± 20.403 | -8.87 ± 16.956 |
| Week 20 | -30.25 ± 21.850 | -23.33 ± 22.600 | -24.35 ± 26.238 | -24.63 ± 21.263 | -11.04 ± 19.653 |
| Week 24 | -31.35 ± 22.434 | -21.82 ± 21.882 | -22.66 ± 27.317 | -25.77 ± 22.085 | -10.45 ± 20.837 |
| Percentage of body surface area | 250 mg KY1005 Re-randomized From the 250mg (LD) Arm (Part 2) | Placebo Re-randomized From the 250mg (LD) Arm (Part 2) | 250 mg KY1005 Re-randomized From the 250mg (No LD) Arm (Part 2) | Placebo Re-randomized From the 250mg (No LD) Arm (Part 2) | 125 mg KY1005 Re-randomized From the 125 mg Arm (Part 2) | Placebo Re-randomized From the 125 mg Arm (Part 2) | 62.5 mg KY1005 Re-randomized From the 62.5 mg Arm (Part 2) | Placebo Re-randomized From the 62.5 mg Arm (Part 2) | Placebo (Part 2) Continued From Part 1 Placebo |
|---|---|---|---|---|---|---|---|---|---|
| Week 24 | -46.92 ± 22.009 | -37.94 ± 18.723 | -37.17 ± 17.994 | -28.14 ± 21.790 | -41.17 ± 22.982 | -33.81 ± 26.454 | -40.60 ± 26.006 | -34.30 ± 19.787 | -32.06 ± 22.831 |
| Week 28 | -48.69 ± 23.329 | -38.68 ± 20.582 | -35.92 ± 20.804 | -25.54 ± 22.718 | -40.00 ± 23.394 | -35.61 ± 25.720 | -37.14 ± 23.801 | -33.62 ± 19.692 | -36.00 ± 24.553 |
| Week 32 | -47.15 ± 25.271 | -36.62 ± 23.049 | -29.64 ± 25.590 | -23.21 ± 23.710 | -42.08 ± 22.685 | -35.94 ± 26.193 | -38.00 ± 23.847 | -32.13 ± 21.515 | -30.07 ± 22.861 |
| Week 36 | -46.00 ± 26.242 | -33.61 ± 24.187 | -28.30 ± 26.437 | -22.21 ± 23.857 | -41.67 ± 23.051 | -35.75 ± 25.664 | -37.86 ± 24.674 | -30.91 ± 24.288 | -31.27 ± 24.391 |
| Week 40 | -46.62 ± 26.314 | -32.94 ± 24.589 | -29.18 ± 24.774 | -22.57 ± 23.841 | -41.45 ± 23.729 | -33.41 ± 22.649 | -39.57 ± 24.758 | -32.00 ± 23.697 | -31.27 ± 24.566 |
| Week 44 | -47.23 ± 26.540 | -33.22 ± 24.143 | -29.73 ± 25.503 | -22.21 ± 23.706 | -42.17 ± 25.283 | -31.91 ± 22.069 | -34.43 ± 25.172 | -32.23 ± 23.250 | -27.43 ± 20.478 |
| Week 48 | -35.69 ± 26.183 | -32.72 ± 25.358 | -28.30 ± 26.378 | -21.50 ± 24.053 | -42.92 ± 25.336 | -30.53 ± 23.544 | -36.43 ± 21.141 | -31.13 ± 26.208 | -26.93 ± 20.775 |
| Week 52 | -35.54 ± 26.384 | -29.48 ± 22.232 | -29.55 ± 25.359 | -21.46 ± 23.562 | -45.09 ± 25.770 | -29.66 ± 23.818 | -34.71 ± 18.688 | -33.33 ± 22.702 | -27.21 ± 20.955 |
| Percentage change | 250 mg (500 mg LD) KY1005 (Part 1) | 250 mg (no LD) KY1005 (Part 1) | 125 mg KY1005 (Part 1) | 62.5 mg KY1005 (Part 1) | Placebo (Part 1) |
|---|---|---|---|---|---|
| Week 2 | -10.11 ± 24.013 | -12.23 ± 26.053 | -19.43 ± 30.139 | -15.06 ± 37.312 | -11.45 ± 22.767 |
| Week 4 | -26.45 ± 28.733 | -23.44 ± 28.941 | -29.46 ± 32.934 | -28.84 ± 38.412 | -20.92 ± 38.260 |
| Week 8 | -39.12 ± 31.915 | -36.01 ± 35.268 | -37.60 ± 36.988 | -42.84 ± 33.931 | -21.24 ± 40.914 |
| Week 12 | -49.88 ± 29.737 | -43.68 ± 38.140 | -47.04 ± 40.519 | -52.16 ± 35.736 | -26.56 ± 36.705 |
| Week 16 | -54.58 ± 32.206 | -49.44 ± 40.861 | -46.35 ± 43.511 | -56.36 ± 35.593 | -22.37 ± 40.483 |
| Week 20 | -59.75 ± 33.804 | -51.07 ± 42.023 | -50.36 ± 45.871 | -53.55 ± 42.762 | -25.46 ± 42.034 |
| Week 24 | -63.02 ± 36.184 | -49.42 ± 43.012 | -48.11 ± 48.748 | -52.94 ± 44.872 | -23.76 ± 44.394 |
| Percentage change | 250 mg KY1005 Re-randomized From the 250mg (LD) Arm (Part 2) | Placebo Re-randomized From the 250mg (LD) Arm (Part 2) | 250 mg KY1005 Re-randomized From the 250mg (No LD) Arm (Part 2) | Placebo Re-randomized From the 250mg (No LD) Arm (Part 2) | 125 mg KY1005 Re-randomized From the 125 mg Arm (Part 2) | Placebo Re-randomized From the 125 mg Arm (Part 2) | 62.5 mg KY1005 Re-randomized From the 62.5 mg Arm (Part 2) | Placebo Re-randomized From the 62.5 mg Arm (Part 2) | Placebo (Part 2) Continued From Part 1 Placebo |
|---|---|---|---|---|---|---|---|---|---|
| Week 24 | -88.09 ± 12.983 | -78.75 ± 27.966 | -80.67 ± 27.843 | -67.85 ± 39.902 | -85.29 ± 19.008 | -71.05 ± 39.900 | -80.52 ± 14.717 | -74.02 ± 31.419 | -72.91 ± 34.317 |
| Week 28 | -90.51 ± 10.816 | -79.51 ± 29.501 | -76.55 ± 35.680 | -62.09 ± 42.748 | -81.75 ± 24.996 | -73.28 ± 40.454 | -88.57 ± 5.800 | -72.98 ± 30.947 | -75.14 ± 37.955 |
| Week 32 | -83.58 ± 23.940 | -75.09 ± 36.907 | -65.07 ± 49.743 | -55.89 ± 45.768 | -86.34 ± 18.724 | -74.61 ± 40.429 | -90.31 ± 10.263 | -66.90 ± 35.357 | -69.74 ± 38.644 |
| Week 36 | -81.56 ± 27.924 | -68.81 ± 40.261 | -61.93 ± 51.222 | -53.48 ± 45.933 | -85.33 ± 18.348 | -74.73 ± 40.570 | -89.70 ± 10.552 | -63.85 ± 46.152 | -72.34 ± 39.621 |
| Week 40 | -82.62 ± 28.019 | -66.33 ± 41.876 | -64.54 ± 49.422 | -54.92 ± 47.035 | -86.81 ± 17.237 | -72.10 ± 41.016 | -94.09 ± 5.083 | -66.00 ± 43.207 | -72.08 ± 39.691 |
| Week 44 | -83.52 ± 28.118 | -66.91 ± 41.122 | -65.39 ± 49.945 | -53.82 ± 46.414 | -84.47 ± 24.104 | -69.38 ± 41.133 | -81.11 ± 19.107 | -66.54 ± 41.241 | -70.30 ± 40.560 |
| Week 48 | -69.37 ± 40.195 | -64.74 ± 42.092 | -62.01 ± 51.359 | -52.52 ± 47.479 | -85.70 ± 19.040 | -64.73 ± 42.700 | -87.79 ± 16.209 | -62.58 ± 48.827 | -68.01 ± 40.428 |
| Week 52 | -68.90 ± 40.301 | -61.59 ± 42.339 | -64.90 ± 49.605 | -52.82 ± 47.733 | -89.06 ± 14.176 | -62.25 ± 42.451 | -85.46 ± 16.921 | -68.75 ± 39.935 | -68.78 ± 41.236 |
POEM is a 7-item (dryness, itching, flaking, cracking, sleep loss, bleeding, and weeping) questionnaire to assess frequency of disease symptoms with a scoring system of 0 to 28. The higher score indicating higher severity
| Score on a scale | 250 mg (500 mg LD) KY1005 (Part 1) | 250 mg (no LD) KY1005 (Part 1) | 125 mg KY1005 (Part 1) | 62.5 mg KY1005 (Part 1) | Placebo (Part 1) |
|---|---|---|---|---|---|
| Week 4 | -4.40 ± 6.403 | -4.01 ± 6.287 | -5.42 ± 6.498 | -4.08 ± 5.448 | -2.32 ± 5.910 |
| Week 8 | -7.03 ± 6.869 | -5.13 ± 7.093 | -5.70 ± 6.943 | -6.75 ± 6.646 | -2.13 ± 6.400 |
| Week 12 | -7.87 ± 7.286 | -6.50 ± 7.229 | -7.29 ± 7.216 | -7.36 ± 7.460 | -2.26 ± 6.088 |
| Week 16 | -8.28 ± 7.286 | -7.23 ± 7.744 | -7.19 ± 7.720 | -7.32 ± 7.017 | -2.37 ± 6.867 |
| Week 20 | -9.39 ± 7.577 | -7.13 ± 8.662 | -8.10 ± 8.150 | -7.39 ± 7.721 | -2.33 ± 6.821 |
| Week 24 | -9.96 ± 7.888 | -7.21 ± 8.213 | -7.86 ± 8.572 | -7.64 ± 7.011 | -2.19 ± 7.310 |
POEM is a 7-item (dryness, itching, flaking, cracking, sleep loss, bleeding, and weeping) questionnaire to assess frequency of disease symptoms with a scoring system of 0 to 28. The higher score indicating higher severity
| Score on a scale | 250 mg KY1005 Re-randomized From the 250mg (LD) Arm (Part 2) | Placebo Re-randomized From the 250mg (LD) Arm (Part 2) | 250 mg KY1005 Re-randomized From the 250mg (No LD) Arm (Part 2) | Placebo Re-randomized From the 250mg (No LD) Arm (Part 2) | 125 mg KY1005 Re-randomized From the 125 mg Arm (Part 2) | Placebo Re-randomized From the 125 mg Arm (Part 2) | 62.5 mg KY1005 Re-randomized From the 62.5 mg Arm (Part 2) | Placebo Re-randomized From the 62.5 mg Arm (Part 2) | Placebo (Part 2) Continued From Part 1 Placebo |
|---|---|---|---|---|---|---|---|---|---|
| Week 24 | -15.31 ± 6.061 | -11.97 ± 6.410 | -11.58 ± 8.586 | -9.25 ± 8.347 | -11.75 ± 7.086 | -10.42 ± 7.580 | -14.00 ± 6.205 | -9.45 ± 7.155 | -8.75 ± 7.197 |
| Week 32 | -14.69 ± 8.499 | -10.23 ± 8.320 | -11.91 ± 8.240 | -6.79 ± 8.875 | -12.83 ± 7.082 | -11.32 ± 8.113 | -11.29 ± 10.323 | -9.42 ± 7.784 | -7.62 ± 8.856 |
| Week 36 | -13.23 ± 8.738 | -9.91 ± 8.129 | -11.90 ± 7.264 | -7.00 ± 8.932 | -13.00 ± 7.019 | -11.75 ± 8.370 | -12.57 ± 9.502 | -8.66 ± 7.790 | -7.93 ± 7.966 |
| Week 40 | -13.92 ± 8.411 | -9.10 ± 8.715 | -11.00 ± 6.633 | -7.82 ± 9.302 | -11.73 ± 8.162 | -11.88 ± 8.698 | -11.29 ± 8.995 | -8.81 ± 8.300 | -7.50 ± 7.714 |
| Week 44 | -13.31 ± 8.460 | -9.81 ± 8.920 | -10.45 ± 6.699 | -6.50 ± 8.804 | -11.92 ± 8.262 | -10.19 ± 8.361 | -7.86 ± 7.515 | -8.71 ± 8.158 | -7.93 ± 7.908 |
| Week 48 | -11.69 ± 9.861 | -10.39 ± 8.519 | -11.50 ± 6.916 | -7.50 ± 9.268 | -11.75 ± 9.836 | -10.33 ± 8.125 | -9.57 ± 9.126 | -9.90 ± 8.660 | -7.50 ± 8.438 |
| Week 52 | -11.85 ± 10.148 | -9.13 ± 8.320 | -11.36 ± 6.889 | -6.82 ± 9.318 | -10.64 ± 10.053 | -8.55 ± 8.240 | -10.00 ± 9.452 | -8.58 ± 9.164 | -8.50 ± 9.146 |
POEM is a 7-item (dryness, itching, flaking, cracking, sleep loss, bleeding, and weeping) questionnaire to assess frequency of disease symptoms with a scoring system of 0 to 28. The higher score indicating higher severity
| Percentage of change | 250 mg (500 mg LD) KY1005 (Part 1) | 250 mg (no LD) KY1005 (Part 1) | 125 mg KY1005 (Part 1) | 62.5 mg KY1005 (Part 1) | Placebo (Part 1) |
|---|---|---|---|---|---|
| Week 4 | -20.81 ± 34.179 | -21.02 ± 31.360 | -22.77 ± 30.783 | -17.94 ± 30.152 | -8.99 ± 39.554 |
| Week 8 | -33.06 ± 41.272 | -26.52 ± 33.397 | -26.62 ± 34.946 | -34.60 ± 31.584 | -6.28 ± 42.851 |
| Week 12 | -36.22 ± 43.169 | -32.42 ± 32.145 | -33.33 ± 33.732 | -34.61 ± 34.275 | -8.04 ± 41.445 |
| Week 16 | -37.08 ± 52.391 | -34.71 ± 34.574 | -32.78 ± 36.449 | -35.49 ± 32.862 | -8.12 ± 45.515 |
| Week 20 | -44.03 ± 38.850 | -34.23 ± 38.938 | -37.38 ± 38.448 | -35.37 ± 36.589 | -8.32 ± 44.942 |
| Week 24 | -44.69 ± 61.808 | -33.91 ± 48.273 | -36.65 ± 40.947 | -36.81 ± 34.444 | -6.98 ± 49.837 |
POEM is a 7-item (dryness, itching, flaking, cracking, sleep loss, bleeding, and weeping) questionnaire to assess frequency of disease symptoms with a scoring system of 0 to 28. The higher score indicating higher severity
| Percentage of change | 250 mg KY1005 Re-randomized From the 250mg (LD) Arm (Part 2) | Placebo Re-randomized From the 250mg (LD) Arm (Part 2) | 250 mg KY1005 Re-randomized From the 250mg (No LD) Arm (Part 2) | Placebo Re-randomized From the 250mg (No LD) Arm (Part 2) | 125 mg KY1005 Re-randomized From the 125 mg Arm (Part 2) | Placebo Re-randomized From the 125 mg Arm (Part 2) | 62.5 mg KY1005 Re-randomized From the 62.5 mg Arm (Part 2) | Placebo Re-randomized From the 62.5 mg Arm (Part 2) | Placebo (Part 2) Continued From Part 1 Placebo |
|---|---|---|---|---|---|---|---|---|---|
| Week 24 | -72.61 ± 19.898 | -61.00 ± 30.657 | -54.05 ± 38.147 | -46.08 ± 37.356 | -60.03 ± 30.545 | -51.61 ± 35.438 | -64.00 ± 20.049 | -45.63 ± 34.579 | -47.92 ± 40.572 |
| Week 32 | -64.90 ± 38.029 | -50.03 ± 44.543 | -56.00 ± 35.875 | -30.61 ± 39.689 | -64.21 ± 28.981 | -55.82 ± 36.229 | -47.30 ± 57.463 | -46.42 ± 38.011 | -43.95 ± 50.962 |
| Week 36 | -60.09 ± 40.508 | -48.61 ± 43.883 | -57.09 ± 34.068 | -33.73 ± 38.724 | -66.78 ± 27.084 | -57.38 ± 37.436 | -57.54 ± 59.987 | -43.35 ± 40.000 | -44.58 ± 45.387 |
| Week 40 | -62.85 ± 38.659 | -44.35 ± 45.524 | -54.47 ± 35.815 | -37.89 ± 40.032 | -58.98 ± 33.289 | -58.12 ± 38.754 | -49.79 ± 55.862 | -43.75 ± 40.933 | -42.88 ± 45.567 |
| Week 44 | -60.83 ± 40.648 | -48.48 ± 47.524 | -52.24 ± 36.218 | -30.25 ± 43.110 | -59.17 ± 35.572 | -50.10 ± 37.814 | -36.09 ± 53.637 | -43.16 ± 39.688 | -46.19 ± 46.429 |
| Week 48 | -54.56 ± 46.380 | -51.53 ± 44.857 | -55.93 ± 35.043 | -35.37 ± 42.309 | -58.18 ± 46.077 | -51.56 ± 39.299 | -44.04 ± 58.904 | -50.45 ± 41.809 | -43.48 ± 48.292 |
| Week 52 | -54.68 ± 45.987 | -44.51 ± 43.725 | -54.47 ± 34.319 | -29.38 ± 46.373 | -52.64 ± 47.556 | -43.45 ± 42.459 | -48.82 ± 63.478 | -43.01 ± 45.577 | -47.62 ± 50.785 |
DLQI is a questionnaire with a score system of 0 to 30 the high score is indicative of poor QoL.
| Score on a scale | 250 mg (500 mg LD) KY1005 (Part 1) | 250 mg (no LD) KY1005 (Part 1) | 125 mg KY1005 (Part 1) | 62.5 mg KY1005 (Part 1) | Placebo (Part 1) |
|---|---|---|---|---|---|
| Week 2 | -3.63 ± 4.992 | -2.82 ± 4.850 | -3.32 ± 5.745 | -3.40 ± 5.131 | -2.09 ± 4.710 |
| Week 8 | -6.13 ± 6.164 | -5.59 ± 5.553 | -5.08 ± 7.252 | -7.13 ± 5.954 | -2.43 ± 5.466 |
| Week 16 | -7.79 ± 6.832 | -6.25 ± 6.246 | -6.47 ± 7.835 | -7.76 ± 6.265 | -2.35 ± 6.069 |
| Week 20 | -7.89 ± 6.848 | -6.42 ± 6.833 | -6.97 ± 8.512 | -7.31 ± 7.132 | -2.39 ± 6.391 |
| Week 24 | -8.33 ± 7.036 | -6.54 ± 6.384 | -6.74 ± 8.681 | -7.69 ± 7.230 | -2.30 ± 6.406 |
DLQI is a questionnaire with a score system of 0 to 30 the high score is indicative of poor QoL.
| Score on a scale | 250 mg KY1005 Re-randomized From the 250mg (LD) Arm (Part 2) | Placebo Re-randomized From the 250mg (LD) Arm (Part 2) | 250 mg KY1005 Re-randomized From the 250mg (No LD) Arm (Part 2) | Placebo Re-randomized From the 250mg (No LD) Arm (Part 2) | 125 mg KY1005 Re-randomized From the 125 mg Arm (Part 2) | Placebo Re-randomized From the 125 mg Arm (Part 2) | 62.5 mg KY1005 Re-randomized From the 62.5 mg Arm (Part 2) | Placebo Re-randomized From the 62.5mg Arm (Part 2) | Placebo (Part 2) Continued From Part 1 Placebo |
|---|---|---|---|---|---|---|---|---|---|
| Week 24 | -12.54 ± 6.703 | -9.00 ± 6.290 | -9.08 ± 6.487 | -7.57 ± 7.295 | -11.42 ± 7.115 | -8.26 ± 9.338 | -15.40 ± 8.562 | -9.67 ± 7.712 | -6.44 ± 7.420 |
| Week 28 | -12.62 ± 8.191 | -9.52 ± 6.929 | -9.83 ± 6.658 | -7.21 ± 6.488 | -11.33 ± 7.832 | -8.45 ± 9.705 | -12.29 ± 9.232 | -9.68 ± 8.029 | -5.77 ± 8.633 |
| Week 32 | -12.38 ± 8.272 | -8.00 ± 7.612 | -8.55 ± 8.238 | -5.75 ± 7.183 | -12.25 ± 7.700 | -8.50 ± 9.629 | -13.14 ± 8.050 | -9.13 ± 7.906 | -5.47 ± 7.963 |
| Week 36 | -11.85 ± 8.122 | -7.72 ± 7.985 | -7.90 ± 6.903 | -6.18 ± 7.222 | -12.58 ± 7.716 | -8.84 ± 9.893 | -14.00 ± 8.446 | -8.53 ± 7.927 | -5.93 ± 7.839 |
| Week 40 | -12.23 ± 7.715 | -7.07 ± 8.073 | -7.18 ± 5.456 | -6.21 ± 7.279 | -11.27 ± 7.976 | -8.06 ± 9.844 | -14.57 ± 7.569 | -8.23 ± 8.281 | -5.36 ± 8.308 |
| Week 44 | -11.38 ± 8.109 | -7.19 ± 7.943 | -8.18 ± 6.258 | -5.68 ± 7.029 | -12.08 ± 8.426 | -6.88 ± 9.587 | -10.29 ± 7.889 | -8.26 ± 8.058 | -5.93 ± 6.889 |
| Week 48 | -9.92 ± 6.800 | -7.29 ± 8.022 | -8.40 ± 7.516 | -6.21 ± 7.218 | -11.92 ± 8.229 | -6.83 ± 9.322 | -11.29 ± 6.237 | -7.93 ± 7.891 | -6.79 ± 7.040 |
| Week 52 | -9.08 ± 6.652 | -6.83 ± 7.852 | -8.09 ± 7.077 | -5.93 ± 7.383 | -12.55 ± 9.136 | -6.41 ± 9.428 | -11.57 ± 6.705 | -8.10 ± 7.752 | -6.64 ± 6.902 |
DLQI is a questionnaire with a score system of 0 to 30 the high score is indicative of poor QoL.
| Percentage of change | 250 mg (500 mg LD) KY1005 (Part 1) | 250 mg (no LD) KY1005 (Part 1) | 125 mg KY1005 (Part 1) | 62.5 mg KY1005 (Part 1) | Placebo (Part 1) |
|---|---|---|---|---|---|
| Week 2 | -22.68 ± 31.305 | -11.95 ± 47.921 | -16.80 ± 41.680 | -22.73 ± 32.711 | -10.30 ± 37.999 |
| Week 8 | -36.87 ± 36.954 | -36.14 ± 41.176 | -27.54 ± 59.199 | -45.85 ± 32.198 | -13.12 ± 42.775 |
| Week 16 | -46.69 ± 40.563 | -41.27 ± 43.616 | -34.02 ± 62.565 | -48.96 ± 29.801 | -11.35 ± 51.739 |
| Week 20 | -47.48 ± 40.616 | -42.90 ± 46.336 | -35.79 ± 67.398 | -44.33 ± 36.816 | -12.08 ± 49.973 |
| Week 24 | -51.84 ± 41.442 | -42.36 ± 45.550 | -33.28 ± 72.816 | -45.63 ± 33.860 | -11.91 ± 55.694 |
DLQI is a questionnaire with a score system of 0 to 30 the high score is indicative of poor QoL.
| Percentage of change | 250 mg KY1005 Re-randomized From the 250mg (LD) Arm (Part 2) | Placebo Re-randomized From the 250mg (LD) Arm (Part 2) | 250 mg KY1005 Re-randomized From the 250mg (No LD) Arm (Part 2) | Placebo Re-randomized From the 250mg (No LD) Arm (Part 2) | 125 mg KY1005 Re-randomized From the 125 mg Arm (Part 2) | Placebo Re-randomized From the 125 mg Arm (Part 2) | 62.5 mg KY1005 Re-randomized From the 62.5 mg Arm (Part 2) | Placebo Re-randomized From the 62.5mg Arm (Part 2) | Placebo (Part 2) Continued From Part 1 Placebo |
|---|---|---|---|---|---|---|---|---|---|
| Week 24 | -75.53 ± 26.705 | -61.64 ± 35.809 | -64.74 ± 31.091 | -44.26 ± 57.217 | -72.47 ± 27.818 | -47.08 ± 82.439 | -70.77 ± 27.653 | -55.36 ± 33.443 | -48.30 ± 57.726 |
| Week 28 | -72.50 ± 37.184 | -62.65 ± 43.216 | -71.77 ± 29.970 | -44.81 ± 56.575 | -70.02 ± 28.760 | -48.86 ± 83.936 | -65.28 ± 26.807 | -55.62 ± 34.382 | -41.13 ± 80.192 |
| Week 32 | -68.19 ± 38.039 | -48.69 ± 56.833 | -61.68 ± 42.315 | -31.65 ± 55.087 | -77.14 ± 26.277 | -50.15 ± 83.141 | -72.98 ± 17.074 | -52.99 ± 36.735 | -41.18 ± 68.097 |
| Week 36 | -65.76 ± 35.792 | -48.12 ± 56.610 | -60.50 ± 41.018 | -35.86 ± 58.071 | -79.13 ± 24.980 | -52.16 ± 84.141 | -78.26 ± 23.932 | -49.48 ± 43.137 | -45.04 ± 65.630 |
| Week 40 | -69.26 ± 34.172 | -44.78 ± 59.798 | -58.29 ± 42.112 | -36.52 ± 58.909 | -72.31 ± 27.268 | -46.41 ± 84.277 | -83.18 ± 16.284 | -49.75 ± 42.024 | -38.69 ± 80.196 |
| Week 44 | -63.03 ± 41.237 | -45.33 ± 60.470 | -63.04 ± 42.005 | -33.25 ± 58.480 | -76.32 ± 31.166 | -39.27 ± 83.804 | -60.44 ± 28.925 | -49.15 ± 43.228 | -48.21 ± 48.871 |
| Week 48 | -59.02 ± 36.676 | -45.68 ± 59.933 | -63.97 ± 43.622 | -35.98 ± 57.915 | -73.10 ± 28.704 | -40.20 ± 84.240 | -70.04 ± 26.437 | -50.82 ± 41.018 | -57.92 ± 45.339 |
| Week 52 | -53.62 ± 36.496 | -43.64 ± 56.804 | -61.04 ± 42.716 | -33.21 ± 59.514 | -72.35 ± 33.768 | -35.27 ± 85.953 | -71.56 ± 28.287 | -49.24 ± 43.003 | -57.12 ± 44.899 |
ADCT is a questionnaire to assess patient-self-perceived control of their eczema with a total score from 0 to 24; higher scores indicate lower AD control
| Score on a scale | 250 mg (500 mg LD) KY1005 (Part 1) | 250 mg (no LD) KY1005 (Part 1) | 125 mg KY1005 (Part 1) | 62.5 mg KY1005 (Part 1) | Placebo (Part 1) |
|---|---|---|---|---|---|
| Week 16 | -6.70 ± 5.813 | -5.41 ± 6.054 | -6.22 ± 6.272 | -6.61 ± 5.804 | -2.50 ± 4.589 |
| Week 24 | -7.35 ± 6.695 | -5.80 ± 6.187 | -6.70 ± 6.566 | -6.66 ± 5.868 | -1.90 ± 5.046 |
ADCT is a questionnaire to assess patient-self-perceived control of their eczema with a total score from 0 to 24; higher scores indicate lower AD control
| Score on a scale | 250 mg KY1005 Re-randomized From the 250mg (LD) Arm (Part 2) | Placebo Re-randomized From the 250mg (LD) Arm (Part 2) | 250 mg KY1005 Re-randomized From the 250mg (No LD) Arm (Part 2) | Placebo Re-randomized From the 250mg (No LD) Arm (Part 2) | 125 mg KY1005 Re-randomized From the 125 mg Arm (Part 2) | Placebo Re-randomized From the 125mg Arm (Part 2) | 62.5 mg KY1005 Re-randomized From the 62.5 mg Arm (Part 2) | Placebo Re-randomized From the 62.5 mg Arm (Part 2) | Placebo (Part 2) Continued From Part 1 Placebo |
|---|---|---|---|---|---|---|---|---|---|
| Week 24 | -11.23 ± 6.071 | -8.64 ± 5.927 | -9.83 ± 6.506 | -7.44 ± 5.673 | -9.83 ± 5.132 | -8.42 ± 6.386 | -12.60 ± 6.986 | -8.29 ± 5.996 | -6.25 ± 6.083 |
| Week 36 | -11.46 ± 5.681 | -8.13 ± 6.463 | -8.20 ± 6.143 | -7.78 ± 6.123 | -10.33 ± 5.483 | -9.26 ± 6.875 | -10.71 ± 6.550 | -8.03 ± 6.385 | -6.38 ± 6.063 |
| Week 52 | -11.31 ± 4.768 | -8.30 ± 5.706 | -8.82 ± 6.809 | -7.44 ± 6.594 | -10.45 ± 5.989 | -6.48 ± 6.539 | -9.71 ± 4.751 | -8.34 ± 6.893 | -7.14 ± 6.125 |
ADCT is a questionnaire to assess patient-self-perceived control of their eczema with a total score from 0 to 24; higher scores indicate lower AD control
| Percentage of change | 250 mg (500 mg LD) KY1005 (Part 1) | 250 mg (no LD) KY1005 (Part 1) | 125 mg KY1005 (Part 1) | 62.5 mg KY1005 (Part 1) | Placebo (Part 1) |
|---|---|---|---|---|---|
| Week 16 | -40.56 ± 37.340 | -33.42 ± 34.745 | -36.42 ± 37.103 | -38.72 ± 30.762 | -17.04 ± 32.553 |
| Week 24 | -45.18 ± 42.438 | -36.20 ± 41.363 | -40.45 ± 40.708 | -39.35 ± 31.799 | -12.31 ± 37.504 |
ADCT is a questionnaire to assess patient-self-perceived control of their eczema with a total score from 0 to 24; higher scores indicate lower AD control
| Percentage of change | 250 mg KY1005 Re-randomized From the 250mg (LD) Arm (Part 2) | Placebo Re-randomized From the 250mg (LD) Arm (Part 2) | 250 mg KY1005 Re-randomized From the 250mg (No LD) Arm (Part 2) | Placebo Re-randomized From the 250mg (No LD) Arm (Part 2) | 125 mg KY1005 Re-randomized From the 125 mg Arm (Part 2) | Placebo Re-randomized From the 125mg Arm (Part 2) | 62.5 mg KY1005 Re-randomized From the 62.5 mg Arm (Part 2) | Placebo Re-randomized From the 62.5 mg Arm (Part 2) | Placebo (Part 2) Continued From Part 1 Placebo |
|---|---|---|---|---|---|---|---|---|---|
| Week 24 | -66.75 ± 32.632 | -57.08 ± 37.656 | -56.01 ± 36.112 | -49.97 ± 34.078 | -65.46 ± 26.823 | -53.10 ± 40.207 | -63.92 ± 29.784 | -50.66 ± 33.458 | -44.95 ± 45.331 |
| Week 36 | -69.01 ± 29.493 | -50.38 ± 42.649 | -50.01 ± 37.199 | -50.87 ± 33.197 | -69.73 ± 28.925 | -58.44 ± 43.340 | -62.63 ± 23.130 | -48.59 ± 38.274 | -49.42 ± 45.902 |
| Week 52 | -69.93 ± 26.250 | -54.77 ± 34.128 | -52.75 ± 41.167 | -47.15 ± 39.681 | -67.84 ± 32.469 | -41.39 ± 43.875 | -64.19 ± 28.274 | -50.29 ± 41.341 | -53.35 ± 47.196 |
The HADS is 14-item questionnaire with two subscales: anxiety \& depression. Each subscale (anxiety \& depression) ranges 0-21. The total HADS score ranges 0-42 with higher score indicating a poorer state.
| Score on a scale | 250 mg (500 mg LD) KY1005 (Part 1) | 250 mg (no LD) KY1005 (Part 1) | 125 mg KY1005 (Part 1) | 62.5 mg KY1005 (Part 1) | Placebo (Part 1) |
|---|---|---|---|---|---|
| Week 8 | -2.20 ± 4.639 | -2.07 ± 6.194 | -2.35 ± 5.641 | -3.29 ± 5.132 | -0.97 ± 3.940 |
| Week 16 | -2.67 ± 5.761 | -2.53 ± 6.510 | -3.04 ± 6.292 | -3.74 ± 6.401 | -0.57 ± 5.088 |
| Week 20 | -2.52 ± 7.254 | -2.35 ± 7.326 | -3.38 ± 6.787 | -4.24 ± 5.873 | -0.66 ± 4.176 |
| Week 24 | -2.96 ± 7.550 | -2.30 ± 6.880 | -2.83 ± 6.818 | -4.00 ± 6.802 | -0.97 ± 4.196 |
The HADS is 14-item questionnaire with two subscales: anxiety \& depression. Each subscale (anxiety \& depression) ranges 0-21. The total HADS score ranges 0-42 with higher score indicating a poorer state.
| score on a scale | 250 mg KY1005 Re-randomized From the 250mg (LD) Arm (Part 2) | Placebo Re-randomized From the 250mg (LD) Arm (Part 2) | 250 mg KY1005 Re-randomized From the 250mg (No LD) Arm (Part 2) | Placebo Re-randomized From the 250mg (No LD) Arm (Part 2) | 125 mg KY1005 Re-randomized From the 125 mg Arm (Part 2) | Placebo Re-randomized From the 125 mg Arm (Part 2) | 62.5 mg KY1005 Re-randomized From the 62.5 mg Arm (Part 2) | Placebo Re-randomized From the 62.5 mg Arm (Part 2) | Placebo (Part 2) Continued From Part 1 Placebo |
|---|---|---|---|---|---|---|---|---|---|
| Week 24 | -4.54 ± 8.482 | -1.73 ± 7.434 | -5.58 ± 10.184 | -2.81 ± 6.822 | -3.67 ± 6.998 | -4.42 ± 7.890 | -8.20 ± 6.340 | -4.03 ± 6.710 | -0.38 ± 4.660 |
| Week 28 | -3.54 ± 7.965 | -2.52 ± 6.205 | -6.50 ± 11.430 | -2.70 ± 6.916 | -4.33 ± 7.679 | -4.97 ± 8.428 | -7.29 ± 5.251 | -5.26 ± 7.034 | 0.38 ± 4.753 |
| Week 32 | -3.38 ± 8.893 | -1.24 ± 6.996 | -4.09 ± 9.027 | -2.74 ± 7.593 | -4.42 ± 7.242 | -5.66 ± 8.280 | -6.86 ± 5.460 | -3.97 ± 6.483 | -0.20 ± 4.491 |
| Week 36 | -1.85 ± 9.754 | -1.22 ± 8.015 | -3.80 ± 10.497 | -2.52 ± 5.833 | -4.42 ± 6.999 | -5.50 ± 8.828 | -7.14 ± 4.880 | -3.75 ± 7.878 | 0.29 ± 4.250 |
| Week 40 | -2.92 ± 8.864 | -1.40 ± 6.966 | -3.09 ± 10.222 | -2.70 ± 6.151 | -3.55 ± 7.594 | -5.16 ± 8.674 | -7.43 ± 5.563 | -3.29 ± 5.593 | 0.50 ± 5.125 |
| Week 44 | -2.69 ± 8.873 | -0.29 ± 6.963 | -3.45 ± 10.511 | -3.07 ± 5.313 | -4.25 ± 7.225 | -4.56 ± 8.879 | -5.43 ± 5.192 | -3.71 ± 7.408 | -0.21 ± 4.318 |
| Week 48 | -3.08 ± 8.883 | -0.68 ± 7.078 | -4.40 ± 10.024 | -2.85 ± 5.559 | -3.33 ± 7.797 | -5.23 ± 8.724 | -7.43 ± 5.412 | -4.17 ± 7.269 | -1.00 ± 4.852 |
| Week 52 | -2.46 ± 9.162 | -0.80 ± 7.092 | -2.55 ± 8.359 | -3.00 ± 5.877 | -4.18 ± 7.167 | -4.59 ± 8.454 | -7.29 ± 5.794 | -3.13 ± 8.082 | -0.64 ± 5.719 |
The HADS is 14-item questionnaire with two subscales: anxiety \& depression. Each subscale (anxiety \& depression) ranges 0-21. The total HADS score ranges 0-42 with higher score indicating a poorer state.
| Percentage of change | 250 mg (500 mg LD) KY1005 (Part 1) | 250 mg (no LD) KY1005 (Part 1) | 125 mg KY1005 (Part 1) | 62.5 mg KY1005 (Part 1) | Placebo (Part 1) |
|---|---|---|---|---|---|
| Week 8 | -18.40 ± 46.151 | -11.76 ± 48.829 | -10.22 ± 56.395 | -13.15 ± 69.427 | -0.66 ± 77.969 |
| Week 16 | -18.12 ± 56.175 | -11.72 ± 54.678 | -15.84 ± 54.001 | -17.47 ± 94.346 | 2.82 ± 101.930 |
| Week 20 | -20.15 ± 65.506 | -7.39 ± 62.693 | -17.62 ± 59.518 | -25.97 ± 83.249 | -5.02 ± 78.180 |
| Week 24 | -13.22 ± 97.953 | -8.67 ± 60.563 | -17.75 ± 52.049 | -12.07 ± 120.061 | -8.17 ± 77.872 |
The HADS is 14-item questionnaire with two subscales: anxiety \& depression. Each subscale (anxiety \& depression) ranges 0-21. The total HADS score ranges 0-42 with higher score indicating a poorer state.
| Percentage of change | 250 mg KY1005 Re-randomized From the 250mg (LD) Arm (Part 2) | Placebo Re-randomized From the 250mg (LD) Arm (Part 2) | 250 mg KY1005 Re-randomized From the 250mg (No LD) Arm (Part 2) | Placebo Re-randomized From the 250mg (No LD) Arm (Part 2) | 125 mg KY1005 Re-randomized From the 125 mg Arm (Part 2) | Placebo Re-randomized From the 125 mg Arm (Part 2) | 62.5 mg KY1005 Re-randomized From the 62.5 mg Arm (Part 2) | Placebo Re-randomized From the 62.5 mg Arm (Part 2) | Placebo (Part 2) Continued From Part 1 Placebo |
|---|---|---|---|---|---|---|---|---|---|
| Week 24 | -28.01 ± 54.369 | -17.89 ± 76.693 | -34.27 ± 48.841 | -13.63 ± 65.697 | -20.28 ± 49.825 | -32.24 ± 65.070 | -46.94 ± 22.063 | -22.38 ± 58.898 | -32.55 ± 66.184 |
| Week 28 | -18.57 ± 53.870 | -22.56 ± 67.645 | -30.97 ± 51.945 | -17.92 ± 53.098 | 4.22 ± 96.782 | -30.52 ± 66.305 | -49.58 ± 31.509 | -33.17 ± 41.412 | -38.39 ± 77.030 |
| Week 32 | -19.06 ± 60.844 | -14.02 ± 82.893 | -29.10 ± 52.035 | -20.31 ± 63.189 | -11.36 ± 87.084 | -43.96 ± 68.306 | -42.56 ± 27.759 | -32.62 ± 49.764 | -38.06 ± 69.176 |
| Week 36 | 11.76 ± 84.979 | -9.44 ± 81.662 | -6.28 ± 62.772 | -22.30 ± 51.020 | -8.75 ± 85.214 | -37.19 ± 71.372 | -51.27 ± 29.960 | -32.59 ± 49.531 | -9.11 ± 110.289 |
| Week 40 | -13.29 ± 60.249 | -18.23 ± 79.025 | 7.25 ± 82.513 | -21.32 ± 50.659 | 4.24 ± 91.941 | -40.11 ± 67.991 | -56.66 ± 33.879 | -35.92 ± 46.888 | -1.02 ± 98.096 |
| Week 44 | -2.42 ± 54.527 | -5.30 ± 88.418 | -23.23 ± 56.824 | -31.88 ± 49.100 | -15.90 ± 85.382 | -30.93 ± 71.891 | -41.44 ± 37.143 | -32.73 ± 57.357 | -22.21 ± 80.062 |
| Week 48 | -14.15 ± 60.660 | -4.47 ± 95.509 | -28.27 ± 51.499 | -21.89 ± 53.010 | 4.97 ± 88.017 | -39.36 ± 69.672 | -60.77 ± 35.190 | -36.32 ± 47.746 | -34.95 ± 67.833 |
| Week 52 | -8.10 ± 67.182 | -7.59 ± 92.868 | -13.70 ± 44.085 | -19.98 ± 56.405 | 0.43 ± 85.522 | -14.22 ± 78.739 | -59.23 ± 37.434 | -23.84 ± 50.933 | -18.16 ± 69.310 |
The pruritus NRS is a simple assessment tool to report the intensity of their pruritus (itch) ranges from 0 to 10 with 0 being 'no itch' and 10 being the 'worst itch imaginable'.
| score on a scale | 250 mg (500 mg LD) KY1005 (Part 1) | 250 mg (no LD) KY1005 (Part 1) | 125 mg KY1005 (Part 1) | 62.5 mg KY1005 (Part 1) | Placebo (Part 1) |
|---|---|---|---|---|---|
| Week 1 | -0.54 ± 1.096 | -0.56 ± 0.978 | -0.49 ± 0.965 | -0.45 ± 0.908 | -0.28 ± 1.071 |
| Week 2 | -0.65 ± 1.316 | -0.79 ± 1.367 | -0.73 ± 1.075 | -0.81 ± 1.224 | -0.42 ± 1.046 |
| Week 3 | -0.90 ± 1.619 | -0.92 ± 1.392 | -1.05 ± 1.302 | -0.88 ± 1.478 | -0.65 ± 1.567 |
| Week 4 | -.096 ± 1.672 | -1.25 ± 1.657 | -1.36 ± 1.443 | -1.09 ± 1.668 | -0.77 ± 1.744 |
| Week 5 | -0.99 ± 1.811 | -1.38 ± 1.653 | -1.42 ± 1.591 | -1.49 ± 1.799 | -0.83 ± 2.030 |
| Week 6 | -1.09 ± 1.679 | -1.35 ± 1.818 | -1.38 ± 1.666 | -1.58 ± 2.057 | -0.94 ± 1.899 |
| Week 7 | -1.25 ± 1.966 | -1.54 ± 1.850 | -1.57 ± 1.710 | -1.78 ± 2.002 | -0.78 ± 1.922 |
| Week 8 | -1.42 ± 2.062 | -1.50 ± 1.786 | -1.60 ± 1.816 | -1.93 ± 2.053 | -0.80 ± 1.979 |
| Week 9 | -1.44 ± 2.104 | -1.52 ± 1.805 | -1.89 ± 1.885 | -2.13 ± 2.031 | -1.00 ± 2.142 |
| Week 10 | -1.62 ± 2.162 | -1.67 ± 1.852 | -1.82 ± 2.082 | -2.17 ± 2.137 | -0.97 ± 2.244 |
| Week 11 | -1.68 ± 2.176 | -1.67 ± 1.936 | -2.06 ± 2.091 | -2.31 ± 2.248 | -0.93 ± 2.111 |
| Week 12 | -1.70 ± 2.204 | -1.65 ± 2.074 | -1.96 ± 2.107 | -2.28 ± 2.262 | -0.79 ± 2.162 |
| Week 13 | -1.83 ± 2.295 | -1.87 ± 2.247 | -2.05 ± 2.164 | -2.28 ± 2.291 | -0.72 ± 2.087 |
| Week 14 | -1.82 ± 2.355 | -2.02 ± 2.468 | -2.13 ± 2.308 | -2.35 ± 2.316 | -0.58 ± 2.055 |
| Week 15 | -1.87 ± 2.386 | -2.08 ± 2.511 | -2.10 ± 2.290 | -2.32 ± 2.288 | -0.57 ± 2.018 |
| Week 16 | -2.06 ± 2.539 | -2.09 ± 2.497 | -2.22 ± 2.275 | -2.31 ± 2.301 | -0.54 ± 2.077 |
| Week 17 | -2.13 ± 2.465 | -2.18 ± 2.457 | -2.14 ± 2.368 | -2.35 ± 2.346 | -0.61 ± 2.143 |
| Week 18 | -2.18 ± 2.534 | -2.21 ± 2.543 | -2.16 ± 2.307 | -2.37 ± 2.383 | -0.55 ± 2.168 |
| Week 19 | -2.19 ± 2.484 | -2.22 ± 2.563 | -2.14 ± 2.291 | -2.38 ± 2.463 | -0.75 ± 2.278 |
| Week 20 | -2.28 ± 2.522 | -2.19 ± 2.530 | -2.13 ± 2.360 | -2.31 ± 2.401 | -0.67 ± 2.201 |
| Week 21 | -2.28 ± 2.516 | -2.23 ± 2.576 | -2.27 ± 2.352 | -2.43 ± 2.404 | -0.76 ± 2.332 |
| Week 22 | -2.38 ± 2.622 | -2.29 ± 2.699 | -2.25 ± 2.438 | -2.44 ± 2.383 | -0.73 ± 2.314 |
| Week 23 | -2.56 ± 2.671 | -2.27 ± 2.538 | -2.20 ± 2.529 | -2.59 ± 2.453 | -0.61 ± 2.215 |
| Week 24 | -2.58 ± 2.662 | -2.30 ± 2.672 | -2.21 ± 2.616 | -2.46 ± 2.427 | -0.55 ± 2.224 |
The pruritus NRS is a simple assessment tool to report the intensity of their pruritus (itch) ranges from 0 to 10 with 0 being 'no itch' and 10 being the 'worst itch imaginable'.
| Score on a scale | 250 mg KY1005 Re-randomized From the 250 mg (LD) Arm (Part 2) | Placebo Re-randomized From the 250 mg (LD) Arm (Part 2) | 250 mg KY1005 Re-randomized From the 250 mg (No LD) Arm (Part 2) | Placebo Re-randomized From the 250 mg (No LD) Arm (Part 2) | 125 mg KY1005 Re-randomized From the 125 mg Arm (Part 2) | Placebo Re-randomized From the 125 mg Arm (Part 2) | 62.5 mg KY1005 Re-randomized From the 62.5 mg Arm (Part 2) | Placebo Re-randomized From the 62.5 mg Arm (Part 2) | Placebo (Part 2) Continued From Part 1 Placebo |
|---|---|---|---|---|---|---|---|---|---|
| Week 24 | -3.63 ± 2.380 | -2.83 ± 2.909 | -4.00 ± 2.711 | -2.25 ± 2.861 | -4.34 ± 2.169 | -2.92 ± 2.539 | -4.63 ± 1.822 | -2.82 ± 2.571 | -1.95 ± 3.083 |
| Week 25 | -3.83 ± 2.353 | -2.73 ± 2.973 | -4.08 ± 2.726 | -2.42 ± 2.895 | -4.12 ± 2.413 | -2.81 ± 2.405 | -4.92 ± 1.863 | -2.64 ± 2.577 | -2.08 ± 3.177 |
| Week 26 | -3.82 ± 2.442 | -2.71 ± 2.891 | -3.75 ± 2.654 | -2.33 ± 3.096 | -3.83 ± 2.428 | -2.56 ± 2.400 | -4.56 ± 1.903 | -2.70 ± 2.634 | -1.93 ± 3.202 |
| Week 27 | -3.84 ± 2.444 | -2.58 ± 2.819 | -3.65 ± 2.619 | -2.28 ± 2.994 | -4.09 ± 2.567 | -2.84 ± 2.467 | -4.51 ± 1.790 | -2.57 ± 2.748 | -2.04 ± 3.351 |
| Week 28 | -3.86 ± 2.432 | -2.56 ± 2.892 | -3.59 ± 2.575 | -2.29 ± 2.782 | -4.02 ± 2.525 | -3.01 ± 2.504 | -4.38 ± 1.827 | -2.75 ± 2.753 | -1.89 ± 3.459 |
| Week 29 | -3.73 ± 2.612 | -2.51 ± 2.874 | -3.81 ± 2.425 | -1.85 ± 2.733 | -4.16 ± 2.387 | -2.99 ± 2.591 | -4.50 ± 2.035 | -2.64 ± 2.695 | -1.81 ± 3.386 |
| Week 30 | -3.32 ± 2.564 | -2.78 ± 3.030 | -3.76 ± 2.394 | -2.07 ± 2.564 | -4.44 ± 2.526 | -2.68 ± 2.490 | -3.73 ± 2.125 | -2.59 ± 2.653 | -1.80 ± 3.445 |
| Week 31 | -3.41 ± 2.580 | -2.74 ± 3.213 | -3.73 ± 2.431 | -1.71 ± 2.980 | -4.18 ± 2.428 | -2.81 ± 2.662 | -4.02 ± 2.280 | -2.78 ± 2.691 | -1.46 ± 3.132 |
| Week 32 | -3.43 ± 2.607 | -2.56 ± 3.098 | -3.13 ± 2.818 | -1.51 ± 2.736 | -4.27 ± 2.261 | -2.86 ± 2.617 | -4.40 ± 2.170 | -2.68 ± 2.674 | -1.54 ± 3.221 |
| Week 33 | -3.60 ± 2.722 | -2.49 ± 3.220 | -3.06 ± 2.755 | -1.85 ± 2.867 | -4.32 ± 2.316 | -2.83 ± 2.579 | -4.14 ± 1.843 | -2.66 ± 2.705 | -1.45 ± 3.332 |
| Week 34 | -3.49 ± 2.644 | -2.26 ± 3.114 | -3.32 ± 2.732 | -1.30 ± 2.792 | -4.43 ± 2.297 | -2.84 ± 2.508 | -3.97 ± 1.948 | -2.58 ± 2.665 | -1.86 ± 3.578 |
| Week 35 | -3.47 ± 2.712 | -2.51 ± 3.219 | -3.09 ± 2.600 | -1.42 ± 2.685 | -4.60 ± 2.497 | -3.01 ± 2.529 | -4.55 ± 2.055 | -2.65 ± 2.674 | -1.86 ± 3.390 |
| Week 36 | -3.48 ± 2.752 | -2.47 ± 3.262 | -2.81 ± 2.693 | -1.64 ± 2.670 | -4.67 ± 2.468 | -2.90 ± 2.527 | -4.14 ± 1.845 | -2.39 ± 2.626 | -1.56 ± 3.318 |
| Week 37 | -3.44 ± 2.726 | -2.53 ± 3.244 | -2.50 ± 2.523 | -1.85 ± 2.758 | -4.51 ± 2.429 | -3.11 ± 2.508 | -4.49 ± 1.992 | -2.33 ± 2.564 | -1.58 ± 3.328 |
| Week 38 | -3.31 ± 3.182 | -2.33 ± 3.159 | -2.06 ± 2.464 | -1.74 ± 2.803 | -4.57 ± 2.505 | -3.16 ± 2.672 | -4.52 ± 2.046 | -2.37 ± 2.548 | -1.64 ± 3.449 |
| Week 39 | -3.34 ± 3.206 | -2.35 ± 3.212 | -2.52 ± 2.462 | -1.81 ± 2.792 | -4.24 ± 2.451 | -3.07 ± 2.548 | -4.66 ± 2.070 | -2.27 ± 2.605 | -1.78 ± 3.350 |
| Week 40 | -3.29 ± 3.245 | -2.26 ± 3.208 | -2.11 ± 2.064 | -1.74 ± 2.697 | -4.24 ± 2.419 | -2.92 ± 2.574 | -2.98 ± 1.946 | -2.38 ± 2.659 | -1.67 ± 3.413 |
| Week 41 | -3.25 ± 3.188 | -2.26 ± 3.213 | -1.82 ± 1.991 | -1.97 ± 2.774 | -4.56 ± 2.344 | -2.67 ± 2.798 | -3.73 ± 2.142 | -2.41 ± 2.697 | -1.64 ± 3.856 |
| Week 42 | -3.21 ± 3.218 | -2.28 ± 3.307 | -2.53 ± 2.603 | -1.91 ± 2.835 | -4.67 ± 2.494 | -2.92 ± 2.876 | -3.78 ± 2.183 | -2.24 ± 2.655 | -2.01 ± 3.719 |
| Week 43 | -3.30 ± 3.246 | -2.27 ± 3.158 | -2.53 ± 2.523 | -1.74 ± 2.821 | -4.64 ± 2.864 | -2.82 ± 2.612 | -3.70 ± 2.063 | -2.22 ± 2.736 | -2.31 ± 3.823 |
| Week 44 | -3.34 ± 3.276 | -2.31 ± 3.196 | -2.37 ± 2.349 | -1.79 ± 2.690 | -4.83 ± 2.484 | -2.81 ± 2.693 | -3.51 ± 2.084 | -2.21 ± 2.656 | -2.01 ± 3.730 |
| Week 45 | -3.63 ± 3.034 | -2.41 ± 3.267 | -1.97 ± 2.110 | -1.87 ± 2.745 | -4.68 ± 2.637 | -2.62 ± 2.636 | -3.58 ± 1.992 | -2.23 ± 2.678 | -1.87 ± 3.752 |
| Week 46 | -3.29 ± 3.359 | -2.46 ± 3.219 | -2.61 ± 2.550 | -1.84 ± 2.679 | -4.41 ± 2.864 | -2.33 ± 2.614 | -3.78 ± 2.146 | -2.28 ± 2.713 | -1.99 ± 4.071 |
| Week 47 | -3.17 ± 3.283 | -2.31 ± 3.183 | -1.95 ± 2.320 | -1.84 ± 2.796 | -4.46 ± 2.830 | -2.30 ± 2.731 | -3.66 ± 2.139 | -2.38 ± 2.645 | -1.78 ± 3.762 |
| Week 48 | -2.82 ± 3.247 | -2.43 ± 3.202 | -2.36 ± 2.366 | -1.84 ± 2.761 | -4.64 ± 2.892 | -2.04 ± 2.636 | -3.96 ± 2.251 | -2.31 ± 2.731 | -2.05 ± 3.716 |
| Week 49 | -2.80 ± 3.230 | -2.27 ± 3.139 | -2.66 ± 2.610 | -2.02 ± 2.909 | -4.68 ± 2.893 | -2.02 ± 2.625 | -3.65 ± 1.938 | -2.46 ± 2.847 | -2.06 ± 3.875 |
| Week 50 | -2.78 ± 3.223 | -2.23 ± 3.218 | -2.44 ± 2.699 | -1.90 ± 2.913 | -4.56 ± 2.923 | -1.87 ± 2.596 | -3.78 ± 2.092 | -2.35 ± 2.788 | -2.16 ± 3.870 |
| Week 51 | -2.67 ± 3.188 | -2.42 ± 3.317 | -2.39 ± 2.399 | -1.80 ± 2.860 | -4.64 ± 3.094 | -1.89 ± 2.692 | -3.66 ± 2.014 | -2.40 ± 2.777 | -2.12 ± 3.883 |
| Week 52 | -2.70 ± 3.119 | -2.17 ± 3.152 | -2.53 ± 2.917 | -1.84 ± 2.779 | -4.74 ± 2.909 | -1.84 ± 2.929 | -3.86 ± 2.135 | -2.33 ± 2.811 | -2.12 ± 3.904 |
The pruritus NRS is a simple assessment tool to report the intensity of their pruritus (itch) ranges from 0 to 10 with 0 being 'no itch' and 10 being the 'worst itch imaginable'.
| Percentage of change | 250 mg (500 mg LD) KY1005 (Part 1) | 250 mg (no LD) KY1005 (Part 1) | 125 mg KY1005 (Part 1) | 62.5 mg KY1005 (Part 1) | Placebo (Part 1) |
|---|---|---|---|---|---|
| Week 1 | -6.26 ± 16.312 | -7.25 ± 13.575 | -6.18 ± 13.809 | -6.05 ± 13.049 | -3.70 ± 16.432 |
| Week 2 | -7.50 ± 20.644 | -10.37 ± 19.307 | -9.86 ± 14.734 | -11.20 ± 18.124 | -5.63 ± 15.340 |
| Week 3 | -11.08 ± 24.712 | -12.11 ± 18.977 | -14.11 ± 17.784 | -12.08 ± 22.244 | -7.89 ± 22.004 |
| Week 4 | -12.16 ± 25.287 | -16.73 ± 22.997 | -18.37 ± 19.932 | -14.95 ± 24.356 | -9.83 ± 24.266 |
| Week 5 | -12.58 ± 27.613 | -18.64 ± 23.725 | -19.20 ± 21.900 | -20.17 ± 25.112 | -10.14 ± 29.071 |
| Week 6 | -13.73 ± 25.374 | -17.59 ± 25.814 | -18.68 ± 22.790 | -21.29 ± 28.179 | -12.43 ± 27.184 |
| Week 7 | -15.89 ± 28.992 | -20.18 ± 25.476 | -21.18 ± 23.816 | -24.03 ± 27.650 | -10.18 ± 28.308 |
| Week 8 | -18.41 ± 31.375 | -19.99 ± 24.992 | -21.14 ± 24.981 | -26.10 ± 27.810 | -10.51 ± 29.803 |
| Week 9 | -18.83 ± 32.003 | -20.36 ± 25.407 | -25.45 ± 24.895 | -29.18 ± 27.455 | -13.34 ± 32.225 |
| Week 10 | -21.19 ± 32.110 | -22.53 ± 25.815 | -24.46 ± 28.280 | -29.43 ± 28.109 | -12.99 ± 33.194 |
| Week 11 | -21.93 ± 31.966 | -22.37 ± 26.321 | -27.67 ± 28.079 | -31.26 ± 29.641 | -12.73 ± 31.638 |
| Week 12 | -22.59 ± 32.927 | -22.05 ± 28.445 | -26.52 ± 28.426 | -31.23 ± 30.323 | -10.62 ± 32.707 |
| Week 13 | -23.88 ± 33.561 | -24.71 ± 30.761 | -28.18 ± 29.401 | -31.36 ± 31.724 | -10.05 ± 32.122 |
| Week 14 | -23.87 ± 34.926 | -26.45 ± 32.870 | -29.19 ± 30.904 | -32.57 ± 31.719 | -7.60 ± 31.351 |
| Week 15 | -24.40 ± 34.899 | -27.46 ± 33.838 | -28.87 ± 31.207 | -32.01 ± 30.980 | -6.87 ± 29.583 |
| Week 16 | -26.85 ± 36.332 | -27.92 ± 33.619 | -30.75 ± 30.460 | -31.97 ± 31.194 | -6.62 ± 30.591 |
| Week 17 | -27.81 ± 35.262 | -29.27 ± 33.331 | -29.68 ± 31.753 | -32.60 ± 31.851 | -7.46 ± 31.529 |
| Week 18 | -28.78 ± 36.738 | -29.49 ± 34.514 | -29.89 ± 31.200 | -32.50 ± 32.096 | -6.37 ± 31.752 |
| Week 19 | -28.98 ± 36.372 | -29.78 ± 35.087 | -29.83 ± 31.632 | -32.77 ± 33.698 | -9.50 ± 33.411 |
| Week 20 | -30.61 ± 37.215 | -29.30 ± 34.365 | -29.48 ± 32.361 | -31.85 ± 32.767 | -8.56 ± 32.725 |
| Week 21 | -30.40 ± 36.928 | -29.63 ± 34.869 | -31.61 ± 32.551 | -33.20 ± 33.098 | -9.71 ± 34.201 |
| Week 22 | -31.81 ± 38.100 | -30.35 ± 36.881 | -31.15 ± 33.763 | -33.28 ± 32.108 | -9.36 ± 34.161 |
| Week 23 | -34.26 ± 38.693 | -30.30 ± 35.236 | -30.52 ± 35.354 | -35.25 ± 33.102 | -7.23 ± 32.486 |
| Week 24 | -34.70 ± 38.656 | -30.44 ± 36.696 | -30.64 ± 36.647 | -33.26 ± 32.433 | -6.66 ± 32.550 |
The pruritus NRS is a simple assessment tool to report the intensity of their pruritus (itch) ranges from 0 to 10 with 0 being 'no itch' and 10 being the 'worst itch imaginable'.
| Percentage of change | 250 mg KY1005 Re-randomized From the 250 mg (LD) Arm (Part 2) | Placebo Re-randomized From the 250 mg (LD) Arm (Part 2) | 250 mg KY1005 Re-randomized From the 250 mg (No LD) Arm (Part 2) | Placebo Re-randomized From the 250 mg (No LD) Arm (Part 2) | 125 mg KY1005 Re-randomized From the 125 mg Arm (Part 2) | Placebo Re-randomized From the 125 mg Arm (Part 2) | 62.5 mg KY1005 Re-randomized From the 62.5 mg Arm (Part 2) | Placebo Re-randomized From the 62.5 mg Arm (Part 2) | Placebo (Part 2) Continued From Part 1 Placebo |
|---|---|---|---|---|---|---|---|---|---|
| Week 24 | -49.61 ± 33.036 | -38.71 ± 44.259 | -52.36 ± 33.258 | -29.76 ± 40.611 | -56.60 ± 24.568 | -42.27 ± 36.685 | -59.49 ± 22.140 | -38.95 ± 34.963 | -29.09 ± 44.653 |
| Week 25 | -52.15 ± 31.579 | -36.78 ± 45.402 | -53.26 ± 33.810 | -31.69 ± 40.647 | -54.31 ± 29.223 | -41.26 ± 34.643 | -63.84 ± 23.417 | -37.04 ± 36.046 | -30.81 ± 46.001 |
| Week 26 | -51.62 ± 32.197 | -36.84 ± 44.342 | -48.88 ± 32.071 | -30.68 ± 42.883 | -50.31 ± 29.134 | -38.14 ± 35.393 | -57.52 ± 22.280 | -37.71 ± 37.451 | -28.48 ± 46.252 |
| Week 27 | -52.09 ± 32.613 | -35.34 ± 44.056 | -47.36 ± 30.909 | -29.42 ± 40.379 | -53.62 ± 30.255 | -42.65 ± 36.665 | -57.00 ± 20.810 | -35.32 ± 38.963 | -29.92 ± 48.506 |
| Week 28 | -52.36 ± 32.642 | -34.80 ± 45.063 | -47.19 ± 31.551 | -30.58 ± 38.398 | -53.08 ± 30.684 | -44.86 ± 36.493 | -56.28 ± 24.247 | -38.37 ± 38.703 | -27.74 ± 49.936 |
| Week 29 | -50.48 ± 35.634 | -34.13 ± 44.735 | -50.29 ± 29.286 | -24.35 ± 38.746 | -54.93 ± 28.705 | -44.31 ± 37.579 | -56.79 ± 23.453 | -36.46 ± 38.211 | -26.40 ± 48.994 |
| Week 30 | -44.79 ± 34.219 | -37.91 ± 46.288 | -49.35 ± 28.435 | -28.00 ± 35.916 | -58.70 ± 30.600 | -40.30 ± 37.098 | -48.05 ± 24.892 | -36.03 ± 38.742 | -26.58 ± 49.832 |
| Week 31 | -46.03 ± 34.355 | -37.18 ± 49.311 | -49.01 ± 28.581 | -21.78 ± 41.439 | -55.77 ± 30.420 | -42.26 ± 39.161 | -52.67 ± 29.311 | -39.45 ± 38.697 | -21.51 ± 44.331 |
| Week 32 | -46.40 ± 35.233 | -34.68 ± 47.719 | -40.69 ± 34.523 | -19.61 ± 37.935 | -57.32 ± 29.140 | -42.64 ± 38.113 | -56.51 ± 27.668 | -37.63 ± 38.453 | -22.64 ± 46.122 |
| Week 33 | -48.66 ± 36.625 | -33.52 ± 48.881 | -39.31 ± 33.036 | -24.61 ± 39.502 | -57.76 ± 29.406 | -42.45 ± 38.100 | -52.89 ± 22.337 | -37.50 ± 39.368 | -21.49 ± 48.348 |
| Week 34 | -47.09 ± 35.098 | -30.56 ± 48.227 | -43.33 ± 34.277 | -17.18 ± 39.855 | -59.41 ± 29.414 | -42.96 ± 37.718 | -50.34 ± 22.937 | -35.63 ± 37.586 | -27.22 ± 51.629 |
| Week 35 | -46.67 ± 36.047 | -33.99 ± 48.416 | -40.21 ± 32.239 | -18.51 ± 37.670 | -61.70 ± 32.381 | -44.99 ± 37.080 | -58.12 ± 24.772 | -36.74 ± 37.592 | -27.11 ± 48.897 |
| Week 36 | -46.63 ± 36.326 | -33.43 ± 48.720 | -36.23 ± 33.872 | -22.43 ± 37.322 | -62.54 ± 31.831 | -43.37 ± 37.251 | -52.78 ± 22.120 | -33.66 ± 38.520 | -22.57 ± 47.897 |
| Week 37 | -45.95 ± 35.161 | -34.42 ± 48.542 | -32.60 ± 31.909 | -25.63 ± 39.489 | -60.49 ± 31.510 | -46.52 ± 37.336 | -58.05 ± 27.565 | -33.22 ± 38.367 | -22.63 ± 48.038 |
| Week 38 | -43.12 ± 42.814 | -31.62 ± 47.534 | -26.80 ± 31.244 | -24.20 ± 40.063 | -60.83 ± 31.559 | -47.17 ± 39.147 | -58.43 ± 27.410 | -33.72 ± 37.516 | -24.07 ± 49.645 |
| Week 39 | -43.54 ± 42.937 | -31.75 ± 48.313 | -32.75 ± 31.185 | -25.49 ± 40.126 | -56.79 ± 31.763 | -46.10 ± 38.082 | -59.36 ± 25.162 | -32.70 ± 38.945 | -25.98 ± 48.229 |
| Week 40 | -42.94 ± 43.748 | -30.52 ± 48.657 | -27.37 ± 25.233 | -24.24 ± 38.972 | -56.78 ± 31.397 | -43.62 ± 38.048 | -38.57 ± 22.074 | -34.20 ± 39.168 | -24.22 ± 49.044 |
| Week 41 | -42.33 ± 43.065 | -30.85 ± 48.900 | -22.99 ± 23.218 | -27.38 ± 39.966 | -61.18 ± 30.487 | -39.66 ± 42.054 | -47.95 ± 26.092 | -34.51 ± 40.123 | -24.13 ± 55.219 |
| Week 42 | -41.68 ± 42.874 | -30.76 ± 50.332 | -34.23 ± 35.319 | -26.33 ± 40.513 | -62.53 ± 32.149 | -42.91 ± 42.866 | -49.33 ± 29.448 | -32.01 ± 39.405 | -29.48 ± 53.423 |
| Week 43 | -42.86 ± 43.495 | -30.51 ± 48.200 | -33.86 ± 33.053 | -23.93 ± 40.455 | -62.27 ± 36.647 | -41.66 ± 38.115 | -48.09 ± 26.148 | -31.34 ± 41.919 | -33.70 ± 54.865 |
| Week 44 | -43.47 ± 44.000 | -31.71 ± 49.607 | -31.76 ± 30.960 | -24.67 ± 37.725 | -64.61 ± 31.787 | -42.36 ± 40.085 | -46.04 ± 28.399 | -31.28 ± 40.103 | -29.07 ± 53.672 |
| Week 45 | -47.27 ± 40.996 | -33.33 ± 50.319 | -25.91 ± 26.492 | -25.91 ± 38.680 | -61.59 ± 33.745 | -39.63 ± 39.211 | -47.19 ± 28.645 | -31.41 ± 39.716 | -27.07 ± 54.016 |
| Week 46 | -42.11 ± 45.119 | -33.68 ± 49.356 | -34.27 ± 33.932 | -25.58 ± 38.019 | -58.81 ± 35.801 | -34.77 ± 38.757 | -49.76 ± 30.190 | -31.98 ± 39.640 | -28.89 ± 58.573 |
| Week 47 | -40.77 ± 44.580 | -31.88 ± 48.778 | -25.60 ± 30.211 | -25.44 ± 39.798 | -59.01 ± 35.211 | -33.49 ± 39.386 | -48.45 ± 30.519 | -33.71 ± 38.282 | -25.86 ± 54.094 |
| Week 48 | -36.53 ± 44.443 | -33.50 ± 48.912 | -30.33 ± 30.351 | -25.04 ± 38.230 | -61.01 ± 35.650 | -29.89 ± 38.681 | -51.75 ± 30.214 | -33.16 ± 40.239 | -29.29 ± 53.432 |
| Week 49 | -36.35 ± 44.233 | -31.23 ± 48.493 | -34.64 ± 34.631 | -28.21 ± 41.352 | -61.21 ± 35.897 | -29.37 ± 38.374 | -48.17 ± 27.760 | -34.32 ± 41.018 | -29.80 ± 55.717 |
| Week 50 | -36.14 ± 44.279 | -31.62 ± 50.758 | -32.01 ± 36.290 | -26.10 ± 40.637 | -59.59 ± 36.330 | -27.45 ± 38.441 | -50.18 ± 30.773 | -32.86 ± 40.330 | -31.15 ± 55.571 |
| Week 51 | -34.31 ± 43.008 | -34.07 ± 51.575 | -30.83 ± 31.211 | -24.47 ± 39.779 | -60.72 ± 38.664 | -27.10 ± 39.790 | -48.66 ± 29.191 | -33.72 ± 40.790 | -30.75 ± 55.841 |
| Week 52 | -35.06 ± 42.961 | -30.54 ± 49.791 | -33.29 ± 38.191 | -25.37 ± 39.165 | -61.83 ± 35.861 | -25.94 ± 43.683 | -50.89 ± 29.752 | -32.36 ± 40.612 | -30.50 ± 56.024 |
The pruritus NRS is a simple assessment tool to report the intensity of their pruritus (itch) ranges from 0 to 10 with 0 being 'no itch' and 10 being the 'worst itch imaginable'.
| Percentage of participants | 250 mg (500 mg LD) KY1005 (Part 1) | 250 mg (no LD) KY1005 (Part 1) | 125 mg KY1005 (Part 1) | 62.5 mg KY1005 (Part 1) | Placebo (Part 1) |
|---|---|---|---|---|---|
| Week 1 | 2.6 | 1.3 | 1.3 | 1.3 | 1.3 |
| Week 2 | 3.9 | 6.4 | 1.3 | 6.3 | 2.5 |
| Week 3 | 9.1 | 6.4 | 10.4 | 7.6 | 6.3 |
| Week 4 | 10.4 | 14.1 | 15.6 | 13.9 | 7.6 |
| Week 5 | 15.6 | 15.4 | 16.9 | 19.0 | 11.4 |
| Week 6 | 10.4 | 19.2 | 18.2 | 21.5 | 12.7 |
| Week 7 | 16.9 | 23.1 | 20.8 | 25.3 | 11.4 |
| Week 8 | 22.1 | 17.9 | 22.1 | 26.6 | 15.2 |
| Week 9 | 20.8 | 19.2 | 27.3 | 31.6 | 13.9 |
| Week 10 | 27.3 | 23.1 | 28.6 | 38.0 | 15.2 |
| Week 11 | 26.0 | 23.1 | 31.2 | 36.7 | 13.9 |
| Week 12 | 26.0 | 20.5 | 28.6 | 38.0 | 16.5 |
| Week 13 | 28.6 | 26.9 | 29.9 | 38.0 | 13.9 |
| Week 14 | 35.1 | 29.5 | 28.6 | 40.5 | 13.9 |
| Week 15 | 29.9 | 28.2 | 28.6 | 40.5 | 10.1 |
| Week 16 | 32.5 | 33.3 | 29.9 | 41.8 | 10.1 |
| Week 17 | 32.5 | 30.8 | 27.3 | 38.0 | 13.9 |
| Week 18 | 36.4 | 33.3 | 29.9 | 43.0 | 12.7 |
| Week 19 | 35.1 | 32.1 | 33.8 | 43.0 | 15.2 |
| Week 20 | 33.8 | 30.8 | 31.2 | 36.7 | 10.1 |
| Week 21 | 37.7 | 32.1 | 33.8 | 36.7 | 15.2 |
| Week 22 | 37.7 | 30.8 | 33.8 | 39.2 | 13.9 |
| Week 23 | 41.6 | 35.9 | 37.7 | 43.0 | 12.7 |
| Week 24 | 40.3 | 30.8 | 36.4 | 39.2 | 11.4 |
The incidence rate of loss of EASI 50 is calculated for participants who achieved EASI 50 at re-randomization (week 24). The incidence rate is computed as the number of participants losing EASI 50 divided by total follow-up time. The follow-up time is defined as the duration from re-randomization (week 24) to either the first event date (loss of EASI 50) or censoring date for participants who had no events. The censoring date is defined as the earliest occurrence of: use of rescue medications and/or selected prohibited medications/ procedures impacting efficacy, or study discontinuation/ completion.
| Events per patient-year | 250 mg KY1005 Re-randomized From the 250 mg (LD) Arm (Part 2) | Placebo Re-randomized From the 250 mg (LD) Arm (Part 2) | 250 mg KY1005 Re-randomized From the 250 mg (No LD) Arm (Part 2) | Placebo Re-randomized From the 250 mg (No LD) Arm (Part 2) | 125 mg KY1005 Re-randomized From the 125 mg Arm (Part 2) | Placebo Re-randomized From the 125 mg Arm (Part 2) | 62.5 mg KY1005 Re-randomized From the 62.5 mg Arm (Part 2) | Placebo Re-randomized From the 62.5 mg Arm (Part 2) | Placebo (Part 2) Continued From Part 1 Placebo |
|---|---|---|---|---|---|---|---|---|---|
| Incidence Rate of Loss of EASI 50 (Part 2) | 0 | 0.272 | 0.188 | 0.089 | 0.165 | 0.071 | 0 | 0.193 | 0.145 |
The incidence rate of loss of EASI 75 is calculated for participants who achieved EASI 75 at re-randomization (week 24). The incidence rate is computed as the number of participants losing EASI 75 divided by total follow-up time. The follow-up time is defined as the duration from re-randomization (week 24) to either the first event date (loss of EASI 75) or censoring date for participants who had no events. The censoring date is defined as the earliest occurrence of: use of rescue medications and/or selected prohibited medications/ procedures impacting efficacy, or study discontinuation/ completion.
| Events per patient-year | 250 mg KY1005 Re-randomized From the 250 mg (LD) Arm (Part 2) | Placebo Re-randomized From the 250 mg (LD) Arm (Part 2) | 250 mg KY1005 Re-randomized From the 250 mg (No LD) Arm (Part 2) | Placebo Re-randomized From the 250 mg (No LD) Arm (Part 2) | 125 mg KY1005 Re-randomized From the 125 mg Arm (Part 2) | Placebo Re-randomized From the 125 mg Arm (Part 2) | 62.5 mg KY1005 Re-randomized From the 62.5 mg Arm (Part 2) | Placebo Re-randomized From the 62.5 mg Arm (Part 2) | Placebo (Part 2) Continued From Part 1 Placebo |
|---|---|---|---|---|---|---|---|---|---|
| Incidence Rate of Loss of EASI 75 (Part 2) | 0 | 0.587 | 0.375 | 0.486 | 0.395 | 0.446 | 0.351 | 0.573 | 0.646 |
The incidence rate of loss of IGA 0/1 is calculated for participants who achieved IGA 0/1 at re-randomization (week 24). The incidence rate is computed as the number of participants losing IGA 0/1 divided by total follow-up time. The follow-up time is defined as the duration from re-randomization (week 24) to either the first event date (loss of IGA 0/1) or censoring date for participants who had no events. The censoring date is defined as the earliest occurrence of: use of rescue medications and/or selected prohibited medications/ procedures impacting efficacy, or study discontinuation/ completion.
| Events per patient-year | 250 mg KY1005 Re-randomized From the 250 mg (LD) Arm (Part 2) | Placebo Re-randomized From the 250 mg (LD) Arm (Part 2) | 250 mg KY1005 Re-randomized From the 250 mg (No LD) Arm (Part 2) | Placebo Re-randomized From the 250 mg (No LD) Arm (Part 2) | 125 mg KY1005 Re-randomized From the 125 mg Arm (Part 2) | Placebo Re-randomized From the 125 mg Arm (Part 2) | 62.5 mg KY1005 Re-randomized From the 62.5 mg Arm (Part 2) | Placebo Re-randomized From the 62.5 mg Arm (Part 2) | Placebo (Part 2) Continued From Part 1 Placebo |
|---|---|---|---|---|---|---|---|---|---|
| Incidence Rate of Loss of IGA 0/1 (Part 2) | 1.267 | 1.039 | 0.981 | 1.930 | 1.154 | 1.045 | 1.096 | 1.790 | 0.244 |
| (ug/ml) | 250 mg (500 mg LD) KY1005 (Part 1) | 250 mg (no LD) KY1005 (Part 1) | 125 mg KY1005 (Part 1) | 62.5 mg KY1005 (Part 1) |
|---|---|---|---|---|
| Baseline | 0.00 ± 0.014 | 0.00 ± 0.014 | 0.01 ± 0.074 | 0.00 ± 0.000 |
| Week 1 | 58.29 ± 24.674 | 30.49 ± 18.520 | 14.18 ± 5.060 | 8.49 ± 3.331 |
| Week 2 | 47.56 ± 17.274 | 25.09 ± 9.041 | 13.56 ± 3.886 | 7.57 ± 2.947 |
| Week 4 | 38.49 ± 22.532 | 19.00 ± 7.869 | 9.67 ± 3.728 | 5.09 ± 2.176 |
| Week 8 | 37.67 ± 15.157 | 32.14 ± 16.502 | 15.07 ± 6.383 | 7.92 ± 3.263 |
| Week 12 | 39.26 ± 33.847 | 34.67 ± 15.191 | 18.12 ± 8.439 | 9.22 ± 4.116 |
| Week 16 | 40.12 ± 28.610 | 38.09 ± 13.536 | 18.39 ± 7.245 | 10.13 ± 4.515 |
| Week 17 | 62.34 ± 28.081 | 64.64 ± 24.169 | 29.26 ± 11.659 | 16.79 ± 6.677 |
| Week 20 | 37.92 ± 14.171 | 48.26 ± 30.691 | 19.31 ± 7.203 | 10.68 ± 3.715 |
| Week 24 | 41.98 ± 23.087 | 43.81 ± 17.403 | 20.25 ± 10.575 | 11.07 ± 3.918 |
| (ug/ml) | 250 mg KY1005 Re-randomized From the 250mg (LD) Arm (Part 2) | Placebo Re-randomized From the 250mg (LD) Arm (Part 2) | 250 mg KY1005 Re-randomized From the 250mg (No LD) Arm (Part 2) | Placebo Re-randomized From the 250mg (No LD) Arm (Part 2) | 125 mg KY1005 Re-randomized From the 125 mg Arm (Part 2) | Placebo Re-randomized From the 125 mg Arm (Part 2) | 62.5 mg KY1005 Re-randomized From the 62.5 mg Arm (Part 2) | Placebo Re-randomized From the 62.5 mg Arm (Part 2) |
|---|---|---|---|---|---|---|---|---|
| Week 24 | 45.13 ± 15.842 | 36.68 ± 17.544 | 45.00 ± 14.568 | 43.17 ± 19.752 | 19.03 ± 9.612 | 19.48 ± 7.791 | 11.60 ± 1.383 | 11.10 ± 5.240 |
| Week 25 | 73.54 ± 30.680 | 36.54 ± 20.508 | 71.25 ± 16.294 | 34.71 ± 14.551 | 31.07 ± 16.115 | 17.57 ± 7.504 | 15.90 ± 2.443 | 10.36 ± 5.145 |
| Week 28 | 51.50 ± 25.454 | 17.59 ± 9.090 | 46.15 ± 15.782 | 25.22 ± 10.235 | 20.12 ± 11.820 | 10.03 ± 4.697 | 9.56 ± 3.485 | 6.66 ± 2.584 |
| Week 32 | 44.41 ± 11.438 | 8.86 ± 5.074 | 41.50 ± 13.681 | 12.54 ± 5.943 | 20.99 ± 12.614 | 4.57 ± 2.463 | 9.40 ± 1.749 | 3.32 ± 1.588 |
| Week 36 | 43.11 ± 18.965 | 5.41 ± 3.876 | 51.42 ± 18.946 | 7.80 ± 4.413 | 22.28 ± 18.101 | 2.85 ± 2.275 | 13.38 ± 2.128 | 1.77 ± 1.018 |
| Week 40 | 45.19 ± 19.921 | 2.42 ± 1.660 | 43.79 ± 15.955 | 4.54 ± 2.929 | 19.09 ± 11.479 | 1.68 ± 1.669 | 10.95 ± 1.350 | 0.96 ± 0.748 |
| Week 44 | 40.91 ± 12.068 | 1.04 ± 0.908 | 46.98 ± 24.015 | 2.62 ± 2.193 | 16.43 ± 7.302 | 0.82 ± 0.863 | 11.25 ± 2.607 | 0.57 ± 0.554 |
| Week 48 | 41.43 ± 14.214 | 0.58 ± 0.507 | 43.63 ± 22.188 | 1.40 ± 1.727 | 17.80 ± 9.065 | 0.42 ± 0.483 | 11.12 ± 1.825 | 0.25 ± 0.305 |
| Week 52 | 38.88 ± 11.526 | 0.56 ± 1.112 | 45.59 ± 22.447 | 0.55 ± 0.573 | 22.60 ± 8.225 | 0.19 ± 0.289 | 12.03 ± 3.775 | 0.11 ± 0.129 |
| Percentage of participants | 250 mg (500 mg LD) KY1005 (Part 1) | 250 mg (no LD) KY1005 (Part 1) | 125 mg KY1005 (Part 1) | 62.5 mg KY1005 (Part 1) | Placebo (Part 1) |
|---|---|---|---|---|---|
| Any Treatment Emergent Adverse Event | 66.2 | 66.7 | 67.5 | 67.9 | 60.3 |
| Any Serious Treatment Emergent Adverse Event | 2.6 | 0 | 1.3 | 6.4 | 1.3 |
| Percentage of participants | 250 mg KY1005 Re-randomized From the 250mg (LD) Arm (Part 2) | Placebo Re-randomized From the 250mg (LD) Arm (Part 2) | 250 mg KY1005 Re-randomized From the 250mg (No LD) Arm (Part 2) | Placebo Re-randomized From the 250mg (No LD) Arm (Part 2) | 125 mg KY1005 Re-randomized From the 125 mg Arm (Part 2) | Placebo Re-randomized From the 125 mg Arm (Part 2) | 62.5 mg KY1005 Re-randomized From the 62.5 mg Arm (Part 2) | Placebo Re-randomized From the 62.5 mg Arm (Part 2) | Placebo (Part 2) Continued From Part 1 Placebo |
|---|---|---|---|---|---|---|---|---|---|
| Any Treatment Emergent Adverse Event | 84.6 | 67.6 | 63.6 | 78.6 | 66.7 | 87.5 | 57.1 | 67.6 | 66.7 |
| Any Serious Treatment Emergent Adverse Event | 7.7 | 2.9 | 0 | 7.1 | 8.3 | 0 | 0 | 0 | 0 |
| Percentage of participants | 250 mg (500 mg LD) KY1005 (Part 1) | 250 mg (no LD) KY1005 (Part 1) | 125 mg KY1005 (Part 1) | 62.5 mg KY1005 (Part 1) |
|---|---|---|---|---|
| Percentage of Participants With Treatment-emergent ADA (Part 1) | 2.6 | 6.4 | 13.2 | 32.1 |
| Percentage of participants | 250 mg KY1005 Re-randomized From the 250 mg (LD) Arm (Part 2) | Placebo Re-randomized From the 250 mg (LD) Arm (Part 2) | 250 mg KY1005 Re-randomized From the 250 mg (No LD) Arm (Part 2) | Placebo Re-randomized From the 250 mg (No LD) Arm (Part 2) | 125 mg KY1005 Re-randomized From the 125 mg Arm (Part 2) | Placebo Re-randomized From the 125 mg Arm (Part 2) | 62.5 mg KY1005 Re-randomized From the 62.5 mg Arm (Part 2) | Placebo Re-randomized From the 62.5 mg Arm (Part 2) |
|---|---|---|---|---|---|---|---|---|
| Percentage of Participants With Treatment-emergent ADA (Part 2) | 7.7 | 9.1 | 9.1 | 19.2 | 0 | 35.5 | 28.6 | 42.4 |
Collected over Treatment Emergent Adverse Events (TEAEs), Treatment Emergent Serious Adverse Events (TESAEs), all-cause mortality (deaths) were collected from the first dose of study treatment (Day 1) up to the last dose of the study treatment (Day 337)+ 140 days safety follow-up for each participant, up to 477 days. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| 250 mg (500 mg LD) KY1005 (Part 1) | 0/77 (0%) | 2/77 (2.6%) | 42/77 (54.5%) |
| 250 mg (no LD) KY1005 (Part 1) | 0/78 (0%) | 0/78 (0%) | 39/78 (50%) |
| 125 mg KY1005 (Part 1) | 0/77 (0%) | 1/77 (1.3%) | 39/77 (50.6%) |
| 62.5 mg KY1005 (Part 1) | 0/78 (0%) | 5/78 (6.4%) | 41/78 (52.6%) |
| Placebo (Part 1) | 0/78 (0%) | 1/78 (1.3%) | 41/78 (52.6%) |
| 250 mg KY1005 Re-Randomized From the 250 mg (LD) Arm (Part 2) | 0/13 (0%) | 1/13 (7.7%) | 11/13 (84.6%) |
| Placebo Re-Randomized From the 250 mg (LD) Arm (Part 2) | 0/34 (0%) | 1/34 (2.9%) | 21/34 (61.8%) |
| 250 mg KY1005 Re-randomized From the 250 mg (No LD) Arm (Part 2) | 0/11 (0%) | 0/11 (0%) | 7/11 (63.6%) |
| Placebo Re-Randomized From the 250 mg (No LD) Arm (Part 2) | 0/28 (0%) | 2/28 (7.1%) | 19/28 (67.9%) |
| 125 mg KY1005 Re-randomized From the 125 mg Arm (Part 2) | 0/12 (0%) | 1/12 (8.3%) | 8/12 (66.7%) |
| Placebo Re-randomized From the 125 mg KY1005 Arm (Part 2) | 0/32 (0%) | 0/32 (0%) | 27/32 (84.4%) |
| 62.5 mg Re-Randomized From the 62.5 mg KY1005 Arm (Part 2) | 0/7 (0%) | 0/7 (0%) | 4/7 (57.1%) |
| Placebo Re-randomized From the 62.5 mg Arm (Part 2) | 0/34 (0%) | 0/34 (0%) | 21/34 (61.8%) |
| Placebo (Part 2) | 0/15 (0%) | 0/15 (0%) | 10/15 (66.7%) |
| Event | 250 mg (500 mg LD) KY1005 (Part 1) | 250 mg (no LD) KY1005 (Part 1) | 125 mg KY1005 (Part 1) | 62.5 mg KY1005 (Part 1) | Placebo (Part 1) | 250 mg KY1005 Re-Randomized From the 250 mg (LD) Arm (Part 2) | Placebo Re-Randomized From the 250 mg (LD) Arm (Part 2) | 250 mg KY1005 Re-randomized From the 250 mg (No LD) Arm (Part 2) | Placebo Re-Randomized From the 250 mg (No LD) Arm (Part 2) | 125 mg KY1005 Re-randomized From the 125 mg Arm (Part 2) | Placebo Re-randomized From the 125 mg KY1005 Arm (Part 2) | 62.5 mg Re-Randomized From the 62.5 mg KY1005 Arm (Part 2) | Placebo Re-randomized From the 62.5 mg Arm (Part 2) | Placebo (Part 2) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Ankle fractureInjury, poisoning and procedural complications | 0/77 | 0/78 | 0/77 | 0/78 | 0/78 | 0/13 | 0/34 | 0/11 | 0/28 | 1/12 | 0/32 | 0/7 | 0/34 | 0/15 |
| Umbilical herniaGastrointestinal disorders | 0/77 | 0/78 | 0/77 | 0/78 | 0/78 | 1/13 | 0/34 | 0/11 | 0/28 | 0/12 | 0/32 | 0/7 | 0/34 | 0/15 |
| Abnormal loss of weightMetabolism and nutrition disorders | 0/77 | 0/78 | 0/77 | 0/78 | 0/78 | 0/13 | 0/34 | 0/11 | 1/28 | 0/12 | 0/32 | 0/7 | 0/34 | 0/15 |
| Rotator cuff syndromeMusculoskeletal and connective tissue disorders | 0/77 | 0/78 | 0/77 | — | 0/78 | 0/13 | 0/34 | 0/11 | 1/28 | 0/12 | 0/32 | 0/7 | 0/34 | 0/15 |
| Spinal osteoarthritisMusculoskeletal and connective tissue disorders | 0/77 | 0/78 | 0/77 | — | 0/78 | 0/13 | 0/34 | 0/11 | 1/28 | 0/12 | 0/32 | 0/7 | 0/34 | 0/15 |
| Tendon ruptureInjury, poisoning and procedural complications | 0/77 | 0/78 | 0/77 | 0/78 | 0/78 | 0/13 | 1/34 | 0/11 | 0/28 | 0/12 | 0/32 | 0/7 | 0/34 | 0/15 |
| Supraventricular tachycardiaCardiac disorders | 1/77 | 0/78 | 0/77 | 0/78 | 0/78 | 0/13 | 0/34 | 0/11 | 0/28 | 0/12 | 0/32 | 0/7 | 0/34 | 0/15 |
| Metabolic acidosisMetabolism and nutrition disorders | 1/77 | 0/78 | 0/77 | — | 0/78 | 0/13 | 0/34 | 0/11 | 0/28 | 0/12 | 0/32 | 0/7 | 0/34 | 0/15 |
| Tension HeadacheNervous system disorders | 1/77 | 0/78 | 0/77 | — | 0/78 | 0/13 | 0/34 | 0/11 | 0/28 | 0/12 | 0/32 | 0/7 | 0/34 | 0/15 |
| Alcohol withdrawal syndromePsychiatric disorders | 1/77 | 0/78 | 0/77 | — | 0/78 | 0/13 | 0/34 | 0/11 | 0/28 | 0/12 | 0/32 | 0/7 | 0/34 | 0/15 |
| Event | 250 mg (500 mg LD) KY1005 (Part 1) | 250 mg (no LD) KY1005 (Part 1) | 125 mg KY1005 (Part 1) | 62.5 mg KY1005 (Part 1) | Placebo (Part 1) | 250 mg KY1005 Re-Randomized From the 250 mg (LD) Arm (Part 2) | Placebo Re-Randomized From the 250 mg (LD) Arm (Part 2) | 250 mg KY1005 Re-randomized From the 250 mg (No LD) Arm (Part 2) | Placebo Re-Randomized From the 250 mg (No LD) Arm (Part 2) | 125 mg KY1005 Re-randomized From the 125 mg Arm (Part 2) | Placebo Re-randomized From the 125 mg KY1005 Arm (Part 2) | 62.5 mg Re-Randomized From the 62.5 mg KY1005 Arm (Part 2) | Placebo Re-randomized From the 62.5 mg Arm (Part 2) | Placebo (Part 2) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| DERMATITIS ATOPICSkin and subcutaneous tissue disorders | 9/77 | 16/78 | 15/77 | 13/78 | 30/78 | 6/13 | 14/34 | 3/11 | 15/28 | 1/12 | 14/32 | 1/7 | 12/34 | 4/15 |
| VIRAL UPPER RESPIRATORY TRACT INFECTIONInfections and infestations | 2/77 | 3/78 | 2/77 | 4/78 | 2/78 | 0/13 | 0/34 | 4/11 | 0/28 | 1/12 | 1/32 | 0/7 | 0/34 | 2/15 |
| NASOPHARYNGITISInfections and infestations | 14/77 | 6/78 | 9/77 | 5/78 | 7/78 | 2/13 | 4/34 | 1/11 | 2/28 | 0/12 | 5/32 | 0/7 | 3/34 | 2/15 |
| HEADACHENervous system disorders | 4/77 | 4/78 | 4/77 | 7/78 | 3/78 | 2/13 | 1/34 | 1/11 | 1/28 | 2/12 | 2/32 | 0/7 | 1/34 | 1/15 |
| CYSTITISInfections and infestations | 0/77 | 1/78 | 0/77 | 0/78 | 1/78 | 0/13 | 0/34 | 0/11 | 0/28 | 0/12 | 0/32 | 1/7 | 0/34 | 0/15 |
| URINARY TRACT INFECTIONInfections and infestations | 0/77 | 1/78 | 0/77 | 0/78 | 0/78 | 0/13 | 1/34 | 1/11 | 0/28 | 0/12 | 0/32 | 1/7 | 0/34 | 0/15 |
| MUSCLE STRAINInjury, poisoning and procedural complications | 0/77 | 0/78 | 0/77 | 0/78 | 0/78 | 0/13 | 0/34 | 0/11 | 0/28 | 0/12 | 0/32 | 1/7 | 0/34 | 0/15 |
| BLOOD CREATINE PHOSPHOKINASE INCREASEDInvestigations | 4/77 | 2/78 | 0/77 | 2/78 | 2/78 | 0/13 | 0/34 | 0/11 | 0/28 | 1/12 | 1/32 | 1/7 | 2/34 | 0/15 |
| BACK PAINMusculoskeletal and connective tissue disorders | 1/77 | 0/78 | 1/77 | 1/78 | 2/78 | 0/13 | 0/34 | 0/11 | 0/28 | 0/12 | 2/32 | 1/7 | 0/34 | 0/15 |
| SPINAL PAINMusculoskeletal and connective tissue disorders | 2/77 | 0/78 | 0/77 | 0/78 | 0/78 | 0/13 | 1/34 | 0/11 | 0/28 | 0/12 | 0/32 | 0/7 | 0/34 | 2/15 |
| Age, Continuous(years) | 250 mg (500 mg LD) KY1005 (Part 1) | 250 mg (No LD) KY1005 (Part 1) | 125 mg KY1005 (Part 1) | 62.5 mg KY1005 (Part 1) | Placebo (Part 1) | Total |
|---|---|---|---|---|---|---|
| Mean | 36.3 ± 13.32 | 40.8 ± 15.24 | 37.9 ± 15.17 | 37.6 ± 14.78 | 36.4 ± 13.07 | 37.8 ± 14.36 |
| Sex: Female, Male(Participants) | 250 mg (500 mg LD) KY1005 (Part 1) | 250 mg (No LD) KY1005 (Part 1) | 125 mg KY1005 (Part 1) | 62.5 mg KY1005 (Part 1) | Placebo (Part 1) | Total |
|---|---|---|---|---|---|---|
| Female | 30 | 35 | 39 | 37 | 30 | 171 |
| Male | 47 | 43 | 38 | 42 | 49 | 219 |
| Race (NIH/OMB)(Participants) | 250 mg (500 mg LD) KY1005 (Part 1) | 250 mg (No LD) KY1005 (Part 1) | 125 mg KY1005 (Part 1) | 62.5 mg KY1005 (Part 1) | Placebo (Part 1) | Total |
|---|---|---|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 0 | 0 | 0 | 0 |
| Asian | 12 | 12 | 10 | 14 | 12 | 60 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 | 0 | 0 | 0 |
| Black or African American | 4 | 2 | 4 | 4 | 6 | 20 |
| White | 61 | 63 | 63 | 60 | 60 | 307 |
| More than one race | 0 | 0 | 0 | 0 | 0 | 0 |
| Unknown or Not Reported | 0 | 1 | 0 | 1 | 1 | 3 |
| EASI Score at Baseline(units on a scale) | 250 mg (500 mg LD) KY1005 (Part 1) | 250 mg (No LD) KY1005 (Part 1) | 125 mg KY1005 (Part 1) | 62.5 mg KY1005 (Part 1) | Placebo (Part 1) | Total |
|---|---|---|---|---|---|---|
| Mean | 30.3 ± 11.66 | 28.7 ± 10.53 | 30.3 ± 12.43 | 28.7 ± 10.09 | 26.4 ± 7.85 | 28.9 ± 10.65 |
Showing the first 100 of 103 sites across 12 countries. Choose a country and city above to see the rest.
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Yes — Qualified researchers may request access to patient level data and related study documents including the clinical study report, study protocol with any amendments, blank case report form, statistical analysis plan, and dataset specifications. Patient level data will be anonymized and study documents will be redacted to protect the privacy of trial participants. Further details on Sanofi's data sharing criteria, eligible studies, and process for requesting access can be found at: https://vivli.org
Supporting information: Study protocol, Statistical analysis plan
Data sharing details ↗ · vivli.org
Ran from Dec 2021 to primary completion in Apr 2023, 16 months.
Results were first posted in Jul 2025, 2 years 2 months after primary completion. A results delay was requested in Apr 2024.
Of 54 industry-sponsored phase 2 interventional studies under Eczema, half reached primary completion within 13 months of starting (the median), counting those still running; a quarter within 9 and three quarters within 16. This study's 16 months is above that.
Counting every sponsor, half of 70 studies reached it within 14 months; a quarter within 10 and three quarters within 26.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jun 2025. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Amlitelimab